{"gene":"STAT1","run_date":"2026-06-10T07:46:42","timeline":{"discoveries":[{"year":1993,"finding":"STAT1 (Stat91) is phosphorylated on a single tyrosine residue (Tyr701) in response to IFN-gamma, and phosphorylation of Tyr701 is required for nuclear translocation, DNA binding, and gene activation. The differentially spliced isoform Stat84, lacking the 38 C-terminal amino acids, was phosphorylated and translocated but did not activate transcription, demonstrating that the C-terminal transactivation domain is essential.","method":"Site-directed mutagenesis, phosphorylation mapping, nuclear translocation assay, transcriptional reporter assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of active-site residue with functional readouts (DNA binding, nuclear translocation, transcription); foundational paper replicated extensively","pmids":["7690989"],"is_preprint":false},{"year":1992,"finding":"STAT1 (91-kDa and 84-kDa proteins) are components of the multiprotein transcription factor ISGF-3, which is cytoplasmically activated by IFN-alpha and translocates to the nucleus to drive interferon-stimulated gene expression. ISGF-3 also contains a 113-kDa protein (STAT2) and a 48-kDa DNA-binding subunit.","method":"Protein purification, peptide sequencing, cDNA cloning, antibody validation (immunoprecipitation)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical purification and molecular cloning of complex components; foundational discovery replicated in multiple companion papers","pmids":["1502203","1502204"],"is_preprint":false},{"year":1994,"finding":"Inactive STAT1 (Stat91) is a monomer in the cytoplasm of unstimulated cells; IFN-gamma-induced Tyr701 phosphorylation drives formation of a stable homodimer. Only the phosphorylated dimer binds specific DNA sequences to activate transcription. Dimerization is mediated through SH2 domain recognition of the phosphotyrosyl peptide on the partner molecule.","method":"Dissociation/reassociation biochemical assays, SH2 mutant analysis, gel-shift DNA-binding assay, analytical biochemistry","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution of dimerization mechanism with mutagenesis; independently confirmed; SH2-pTyr interaction mechanism established with multiple methods","pmids":["7510216"],"is_preprint":false},{"year":1994,"finding":"ISGF-3 formation requires phosphorylated Stat91 (STAT1); mutations blocking Tyr701 phosphorylation of the 91-kDa protein prevent ISGF-3 assembly. Stat113 (STAT2) is phosphorylated independently of Stat91/84, but phosphorylated STAT2 alone translocates to the nucleus much less efficiently in the absence of phosphorylated Stat91/84.","method":"Cell lines lacking Stat91/84, site-directed mutagenesis, co-immunoprecipitation, nuclear fractionation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic complementation with mutant cell lines and mutagenesis; multiple orthogonal methods","pmids":["8197134"],"is_preprint":false},{"year":1994,"finding":"JAK1 kinase is required for tyrosine phosphorylation of STAT1 (84- and 91-kDa) and STAT2 in response to both IFN-alpha/beta and IFN-gamma signaling. Mutant HeLa cells deficient in JAK1 fail to phosphorylate STAT1 on tyrosine and fail to mount a biological IFN response.","method":"Mutant cell line complementation analysis, immunoprecipitation, tyrosine phosphorylation assays, cell fusion analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic complementation in mutant cells; pathway position established; multiple methods","pmids":["8114747"],"is_preprint":false},{"year":1998,"finding":"PIAS1 specifically inhibits STAT1-mediated gene activation by blocking the DNA-binding activity of activated STAT1. PIAS1 physically associates with phosphorylated STAT1 (requiring Tyr701 phosphorylation) but not with STAT2 or STAT3. Other PIAS family members do not bind STAT1.","method":"Co-immunoprecipitation, electrophoretic mobility shift assay (DNA-binding), transcriptional reporter assay, Tyr701 mutant analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, functional DNA-binding assay, mutagenesis to identify phosphorylation requirement; multiple orthogonal methods","pmids":["9724754"],"is_preprint":false},{"year":1998,"finding":"STAT1 is cleaved by a caspase during apoptosis (induced by double-stranded RNA and other apoptotic stimuli). The cleavage product is no longer able to mediate interferon-activated signal transduction.","method":"In vitro caspase cleavage assay, IFN signaling functional assay, apoptosis induction","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical demonstration of caspase cleavage with functional loss-of-signaling readout; single lab","pmids":["9535846"],"is_preprint":false},{"year":2003,"finding":"Nuclear accumulation of phosphorylated STAT1 involves two separate steps: nuclear import and nuclear retention (mediated by nonspecific DNA binding of activated STAT1). Tyrosine dephosphorylation of STAT1 is required for nuclear export; DNA binding protects STAT1 from dephosphorylation in a sequence-specific manner. STAT1 undergoes continuous nucleocytoplasmic cycling sustained by kinase activity.","method":"Microinjection of recombinant STAT1, kinase/phosphatase inhibitor treatment, nuclear accumulation mutant characterization, antibody microinjection","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution by microinjection of recombinant protein, multiple mutants tested, pharmacological perturbations; single lab but multiple orthogonal approaches","pmids":["12923054"],"is_preprint":false},{"year":2003,"finding":"STAT1 translocation from the plasma membrane to the nuclear pore occurs by energy-independent diffusion (random walk), independent of the actin cytoskeleton or microtubules. Nuclear STAT1-GFP shows high mobility consistent with rapid association/dissociation with DNA and/or protein complexes.","method":"FRAP, FLIP, live-cell fluorescence microscopy with STAT1-GFP fusion protein, cytoskeletal disruption","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct live-cell imaging (FRAP/FLIP) with functional fusion protein; mechanistically informative localization experiment","pmids":["11350940"],"is_preprint":false},{"year":2003,"finding":"Nuclear import and export signals of STAT1 reside within its DNA-binding domain. After phosphorylation and dimerization, STAT1's nuclear localization signal is revealed. Upon dephosphorylation and DNA dissociation in the nucleus, a CRM1-dependent nuclear export signal becomes accessible, mediating recycling to the cytoplasm.","method":"Domain mapping, export inhibitor studies, mutant STAT1 analysis","journal":"Science's STKE","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — review summarizing prior experimental findings; single functional data source; mechanistic conclusions supported by cited experiments but this paper is a review","pmids":["12915721"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of unphosphorylated STAT1 (residues 1-683) complexed with an IFNgamma receptor phosphopeptide determined at 3.0 Å resolution. Unphosphorylated STAT1 is predominantly dimeric, mediated by N-domain (residues 1-123) interactions. Two interconvertible orientations of the core fragment are observed ('antiparallel' and 'parallel'), depending on SH2 domain orientation. The SH2 domain interaction with the IFNgamma receptor docking site is structurally resolved.","method":"X-ray crystallography (3.0 Å), static light scattering, analytical ultracentrifugation, co-immunoprecipitation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with orthogonal biophysical validation (AUC, light scattering, co-IP); multiple methods in one study","pmids":["15780933"],"is_preprint":false},{"year":2005,"finding":"STAT1 functions as a cytoplasmic attenuator of Runx2 (a key transcription factor for osteoblast differentiation) independently of IFN signaling. Loss of Stat1 in mice leads to excessive Runx2 activation and increased osteoblast differentiation, resulting in increased bone mass.","method":"Stat1-knockout mice, osteoblast differentiation assays, Runx2 nuclear translocation analysis","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with specific cellular phenotype and identified mechanism (cytoplasmic Runx2 attenuation); review paper summarizing original experimental findings","pmids":["15546140"],"is_preprint":false},{"year":2006,"finding":"STAT1 is an acetylated protein; acetylation is regulated by the balance between CBP (HAT) and HDACs. Both HDAC inhibitors and IFN-alpha induce STAT1 acetylation at Lys410 and Lys413. Only acetylated STAT1 interacts with NF-kappaB p65, reducing p65 DNA binding, nuclear localization, and expression of anti-apoptotic NF-kappaB target genes.","method":"STAT1 acetylation mutants (Lys410/413), co-immunoprecipitation, HDAC/HAT inhibitor treatment, reporter gene assay, DNA-binding assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis identifying acetylation sites, functional readouts (NF-κB binding/activity), biochemical interaction; multiple orthogonal methods in one study","pmids":["16481475"],"is_preprint":false},{"year":2009,"finding":"A phosphorylation-acetylation switch regulates STAT1 signaling: CBP-mediated acetylation of STAT1 counteracts IFN-induced STAT1 phosphorylation, nuclear translocation, DNA binding, and target gene expression. Acetylation of STAT1 induces binding of T-cell protein tyrosine phosphatase (TC45/TCP45), which catalyzes dephosphorylation of STAT1 and promotes latency. HDAC3 removes the acetyl group, allowing re-phosphorylation.","method":"Biochemical assays, STAT1 acetylation/phosphorylation mutants, HAT/HDAC activity modulation, co-immunoprecipitation, transcriptional reporter assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis, biochemical reconstitution of the switch, identification of TC45 as the phosphatase recruited by acetylated STAT1; multiple orthogonal methods","pmids":["19171783"],"is_preprint":false},{"year":2010,"finding":"STAT1 directly interacts with cyclin D1 and CDK4 (G1 cell cycle regulatory proteins). IFN-gamma treatment reduces cyclin D1 protein levels via the proteasome pathway in a manner requiring STAT1 Ser727 (not Tyr701). This interaction and proteasomal degradation of cyclin D1 mediate cell cycle arrest, correlating with decreased pRb, cyclin E and increased p27 and p21.","method":"Co-immunoprecipitation, proteasome inhibitor treatment, STAT1 mutant analysis (Ser727, Tyr701), STAT1-deficient cell lines","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct co-IP of STAT1-cyclin D1/CDK4, site-specific mutagenesis, loss-of-function cell lines; single lab","pmids":["21084836"],"is_preprint":false},{"year":1994,"finding":"Growth hormone (GH) rapidly induces tyrosine phosphorylation and nuclear translocation of STAT91 (STAT1) in vivo in rat liver. Activated STAT1 in the nucleus acquires DNA-binding activity toward a c-sis-inducible element (SIE) from the c-fos promoter, establishing that GH activates the STAT1 pathway.","method":"Western blotting of nuclear extracts, anti-phosphotyrosine immunoprecipitation, gel-mobility shift assay, in vivo GH treatment model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with nuclear fractionation, direct DNA-binding assay; single lab, two orthogonal methods","pmids":["7510676"],"is_preprint":false},{"year":1994,"finding":"Angiotensin II acting through the AT1A receptor (a G-protein-coupled receptor) activates STAT1 (Stat91) or a related protein, inducing tyrosine phosphorylation and nuclear translocation of STAT1 and stimulating SIE-dependent DNA-binding activity. This response is sensitive to tyrosine kinase inhibition (genistein) and independent of new protein synthesis.","method":"Electrophoretic mobility shift assay (EMSA), subcellular fractionation, immunoprecipitation, tyrosine kinase inhibitor studies","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — EMSA plus fractionation plus inhibitor experiments; single lab, GPCR activation of STAT1 pathway established but mechanism upstream of STAT1 not fully resolved","pmids":["7527386"],"is_preprint":false},{"year":2004,"finding":"PKCdelta activates STAT1 via phosphorylation of Ser727 in response to DNA damage (etoposide). STAT1 associates with PKCdelta, and nuclear co-localization of PKCdelta and STAT1 is required for PKCdelta-mediated apoptosis. STAT1beta lacking Ser727 does not support PKCdelta-induced apoptosis in STAT1-deficient cells.","method":"Co-immunoprecipitation, PKCdelta inhibition/depletion, STAT1 Ser727 mutant, STAT1-deficient cell line (U3A) complementation, transcriptional reporter assay, nuclear localization mutants","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, genetic rescue with site-specific mutants, loss-of-function complementation; single lab with multiple orthogonal methods","pmids":["15322115"],"is_preprint":false},{"year":2006,"finding":"STAT1 can be SUMOylated in vitro at Lys703 within the consensus SUMO site (702-IKTE-705). Mutation of K703 (K703R) in STAT1 enhances DNA binding and nuclear retention in STAT1-deficient MEFs, with modest effects on transcription and antiviral activity. Mutation of E705 (E705A) does not alter STAT1 activity, suggesting SUMO modification at Lys703 has limited physiological significance in vivo.","method":"In vitro SUMOylation assay, STAT1 mutant expression in STAT1-/- MEFs and macrophages, DNA-binding assay, nuclear retention assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of SUMOylation, mutant complementation in primary cells; results suggest limited in vivo relevance","pmids":["16857984"],"is_preprint":false},{"year":2014,"finding":"JAK/STAT1 pathway activation promotes HMGB1 hyperacetylation at its two nuclear localization sequences (NLS) and induces HMGB1 translocation from nucleus to cytoplasm. Pharmacological inhibition or genetic deletion of STAT1 abrogates LPS- or type I IFN-induced HMGB1 NLS acetylation and nuclear translocation.","method":"Mass spectrometry acetylation mapping, JAK inhibitor treatment, STAT1 genetic knockout, subcellular fractionation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry-based acetylation site mapping, genetic STAT1 knockout, pharmacological inhibition; multiple orthogonal methods","pmids":["24469805"],"is_preprint":false},{"year":2016,"finding":"PARP14 mediates ADP-ribosylation of STAT1, which is suppressed by PARP9. ADP-ribosylation of STAT1 by PARP14 reduces STAT1 phosphorylation; mutations at ADP-ribosylation sites lead to increased STAT1 phosphorylation. PARP9 and PARP14 cross-regulate macrophage activation via this STAT1 ADP-ribosylation mechanism.","method":"Global proteomics, ADP-ribosylation assay, PARP9/14 silencing, phosphorylation analysis, site-directed mutagenesis of ADP-ribosylation sites","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical demonstration of ADP-ribosylation of STAT1 by PARP14, mutagenesis confirming functional sites, PARP9 antagonism; multiple methods in one study","pmids":["27796300"],"is_preprint":false},{"year":2020,"finding":"STAT1 undergoes linear ubiquitination at Lys511 and Lys652 by the LUBAC complex (via HOIP), which inhibits STAT1 binding to the IFN receptor IFNAR2, restricting STAT1 activation and maintaining type-I IFN signaling homeostasis. The deubiquitinase OTULIN removes linear ubiquitin from STAT1 upon IFN stimulation to facilitate activation. Viruses induce HOIP expression via NF-κB, thereby increasing STAT1 linear ubiquitination and suppressing antiviral IFN responses.","method":"Linear ubiquitination assay in intact cells, site-directed mutagenesis (K511, K652), OTULIN/HOIP knockdown and overexpression, IFNAR2 binding assay, HOIL-1L heterozygous mouse model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical ubiquitination assay, mutagenesis of sites, deubiquitinase rescue, receptor-binding assay, in vivo mouse validation; multiple orthogonal methods","pmids":["32123171"],"is_preprint":false},{"year":2020,"finding":"RNF220 E3 ubiquitin ligase mediates K63-linked polyubiquitination of STAT1 at residue Lys110, which promotes the interaction between STAT1 and JAK1, thereby enhancing STAT1 phosphorylation and activation. RNF220 deficiency impairs IFN signaling and ISG expression.","method":"Co-immunoprecipitation, K63-specific ubiquitination assay, site-directed mutagenesis (K110), RNF220 knockout cells and mice, JAK1-STAT1 interaction assay","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical ubiquitination assay with K63-linkage specificity, mutagenesis, JAK1 interaction assay, in vivo knockout; multiple orthogonal methods","pmids":["32814877"],"is_preprint":false},{"year":2021,"finding":"Syk tyrosine kinase, acting downstream of RIG-I/MAVS signaling, directly phosphorylates STAT1 at Tyr701 at the early stage of influenza A virus infection independently of cytokines and JAKs. Syk deletion attenuates STAT1 phosphorylation and ISG expression; STAT1-Y701F knockin mice have suppressed antiviral response.","method":"Syk deletion (in vitro and in vivo), STAT1-Y701F knockin mice, RIG-I/MAVS pathway analysis, tyrosine phosphorylation assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic deletion and knockin mouse models with specific pathway placement; multiple in vitro and in vivo methods","pmids":["33472080"],"is_preprint":false},{"year":1998,"finding":"Stat1-2 heterodimers form heterotetramers on tandem GAS sites through protein-protein interactions mediated by N-terminal regions of both Stat1 and Stat2. Deletion of 40 N-terminal amino acids from Stat1 abolishes heterotetramer formation without affecting heterodimer formation. ISGF3 also shows cooperative binding to tandem ISREs via N-terminal domain interactions.","method":"EMSA with tandem DNA elements, N-terminal deletion mutants, cooperative binding assays","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain deletion mutagenesis with DNA-binding assay; cooperative binding mechanism defined; single lab","pmids":["9865492"],"is_preprint":false},{"year":2019,"finding":"PHLPP1 phosphatase dephosphorylates STAT1 at Ser727 in the nucleus, inhibiting STAT1 transcriptional activity, reducing its promoter residency, and decreasing expression of target genes involved in innate immunity. This function requires a bipartite nuclear localization signal in PHLPP1's N-terminal extension.","method":"PHLPP1 gene deletion (knockout mice), phosphorylation assays, chromatin immunoprecipitation (promoter occupancy), gene expression analysis, nuclear localization signal mapping","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout with specific Ser727 phosphorylation readout, ChIP for promoter occupancy, mechanistic NLS mapping; multiple orthogonal methods","pmids":["31408005"],"is_preprint":false},{"year":2016,"finding":"NKLAM E3 ubiquitin ligase mediates K63-linked ubiquitination of STAT1 at the IFNgamma receptor complex, which is required for STAT1 DNA-binding activity. NKLAM-deficient macrophages show hyperphosphorylated JAK1 and STAT1 but reduced STAT1 DNA-binding ability and reduced IFNgamma-target gene expression. NKLAM is transiently localized to the IFNgamma receptor complex during stimulation.","method":"K63-specific ubiquitination assay, co-immunoprecipitation, NKLAM-KO macrophages, DNA-binding (GAS sequence) assay, gene expression analysis","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical ubiquitination assay, receptor complex co-IP, DNA-binding functional assay; single lab","pmids":["27570112"],"is_preprint":false},{"year":2016,"finding":"STAT1 directly binds a regulatory element (NRE1) in the first intron of the Nampt gene during IFNgamma stimulation, driving NAMPT expression. NAMPT, the rate-limiting enzyme in NAD salvage synthesis, supports STAT1-dependent M1 macrophage gene expression through its impact on glycolytic processes.","method":"Chromatin immunoprecipitation (ChIP), NRE1 disruption mouse model, NAMPT inhibition, scRNAseq","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishing direct STAT1 binding, in vivo NRE1 disruption model; single lab","pmids":["33976173"],"is_preprint":false},{"year":2016,"finding":"STAT1 transcriptionally suppresses ULK1 (a kinase that controls autophagy initiation) by binding a regulatory sequence in the ULK1 5'-flanking region; mutation of this sequence increases ULK1 promoter activity and renders it unresponsive to mTOR inhibition. STAT1-deficient cells and mice show enhanced autophagic flux and increased ULK1 expression.","method":"Chromatin immunoprecipitation, promoter reporter assay with site mutation, STAT1-deficient cells and mice, autophagic flux measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP + promoter mutagenesis + genetic KO in vitro and in vivo; multiple orthogonal methods","pmids":["28011640"],"is_preprint":false},{"year":2019,"finding":"STAT1 (pSTAT1) directly binds the FOXM1 promoter to transcriptionally down-regulate FOXM1 expression, as demonstrated by dual-luciferase reporter and ChIP assays. IFNgamma-mediated STAT1 phosphorylation suppresses FOXM1 and sensitizes pancreatic cancer cells to gemcitabine.","method":"Chromatin immunoprecipitation, dual-luciferase reporter assay, IFNgamma treatment, in vitro and in vivo cell models","journal":"Clinical science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay establishing direct STAT1 binding to FOXM1 promoter; single lab","pmids":["30782607"],"is_preprint":false},{"year":2020,"finding":"In naive cells, unphosphorylated STAT2 forms a heterodimer with unphosphorylated STAT1 in an inactive anti-parallel conformation. A novel phosphorylation of STAT2 at Thr404 (mouse Thr403) by IKK-epsilon (activated by viral infection) disrupts this U-STAT1-U-STAT2 dimer, facilitating tyrosine phosphorylation of STAT1 and STAT2 and enhancing ISGF3 DNA-binding activity. Mice with T403A knockin are highly susceptible to viral infection.","method":"Electron microscopy structural analysis, site-directed mutagenesis (T404A), IKK-epsilon kinase assay, T403A knockin mice, ISGF3 DNA-binding assay","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EM structure plus mutagenesis plus in vivo knockin mouse phenotype; multiple orthogonal methods in one study","pmids":["32759968"],"is_preprint":false},{"year":2023,"finding":"Nuclear RNA helicase DHX9 directly binds STAT1 upon IFN stimulation and recruits RNA Pol II to interferon-stimulated gene (ISG) promoter regions to facilitate STAT1-mediated ISG transcription. In vivo DHX9 knockout (myeloid- or hepatocyte-specific) combined with STAT1 knockout demonstrates that DHX9 acts downstream of type I IFN and requires STAT1 for antiviral gene regulation.","method":"Co-immunoprecipitation of DHX9-STAT1, chromatin immunoprecipitation (Pol II recruitment), conditional DHX9/STAT1 double-knockout mice, antiviral challenge","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ChIP, epistatic genetic knockouts; single lab","pmids":["36735791"],"is_preprint":false},{"year":2017,"finding":"STAT1 acts downstream of PDGFRbeta signaling to mediate autoinflammation and tissue wasting. Genetic knockout of Stat1 in Pdgfrb gain-of-function mice rescues autoinflammation and converts the wasting phenotype to overgrowth. Deletion of IFN receptors (Ifnar1 or Ifngr1) does not rescue the Pdgfrb wasting phenotype, demonstrating that STAT1 mediates PDGFRbeta-driven autoinflammation independently of IFN receptor signaling.","method":"Genetic epistasis (Stat1-/- x Pdgfrb+/D849V double mutants), Ifnar1 and Ifngr1 knockout crosses, phenotypic analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic epistasis with multiple knockout combinations; IFN-independence established by receptor deletion; replicated in multiple cross-bred mouse lines","pmids":["28924035"],"is_preprint":false},{"year":2024,"finding":"LPS-induced Toll-like receptor 4 endocytosis activates IκB kinase (IKK), which phosphorylates STAT1 at Thr748. This Thr748 phosphorylation promotes macrophage inflammatory responses while restricting IFN and anti-inflammatory responses. Phospho-deficient T748A knockin mice are resistant to LPS-induced lethality without disrupting canonical IFN-Tyr701 signaling, establishing Thr748 as an IFN-independent inflammatory phosphorylation switch.","method":"Genetically engineered T748A knockin mice, IKK kinase assay, LPS challenge model, macrophage depletion, phosphorylation site-specific analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — knockin mouse with defined point mutation, in vitro kinase assay, in vivo lethality model with macrophage depletion rescue; multiple methods","pmids":["38621137"],"is_preprint":false},{"year":2019,"finding":"STAT1 gain-of-function (GOF) pathogenic variants cause elevated total STAT1 protein levels (via increased STAT1 mRNA) rather than impaired dephosphorylation. The rate of STAT1 dephosphorylation after JAK inhibition is actually faster in GOF patient cells than healthy controls. The elevated peak pSTAT1 in GOF patients is driven by higher total STAT1 protein available for phosphorylation.","method":"Flow cytometry (total STAT1 protein), immunoblot, qRT-PCR (mRNA), cycloheximide chase (protein degradation), JAK inhibitor (ruxolitinib) dephosphorylation kinetics in patient PBMCs","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in patient cells; challenges prior delayed-dephosphorylation hypothesis; single study","pmids":["31354696"],"is_preprint":false},{"year":2021,"finding":"CCT6A interacts with STAT1 protein and protects it from ubiquitin-mediated proteasomal degradation, thereby stabilizing STAT1. Stabilized STAT1 then promotes transcription of hexokinase 2 (HK2), driving aerobic glycolysis in lung adenocarcinoma cells.","method":"Co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation, ubiquitination assay, CCT6A silencing","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, MS, ChIP, and ubiquitination assay; single lab with multiple methods","pmids":["38750462"],"is_preprint":false},{"year":2022,"finding":"ADAP (adhesion and degranulation-protein adaptor protein) interacts with STAT1 and competes with importin alpha5 for STAT1 binding, thereby restraining STAT1 nuclear entry. ADAP deficiency potentiates STAT1 nuclear translocation, leading to enhanced FcγRI/IV transcription and increased macrophage phagocytosis. Pharmacological inhibition of STAT1 or disruption of the STAT1-importin alpha5 interaction relieves thrombocytopenia in Adap-/- mice.","method":"Co-immunoprecipitation (ADAP-STAT1-importin α5 complex), ADAP-/- mice, STAT1 nuclear translocation assay, FcγR gene expression, pharmacological STAT1 inhibition","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP establishing ternary complex, genetic knockout with defined phenotype, pharmacological rescue; single lab","pmids":["35637282"],"is_preprint":false},{"year":2023,"finding":"STAT1 transcriptionally suppresses ULK1 (Ulk1) expression in microglia. Alpha-synuclein PFF activates STAT1 through Toll-like receptor 4-dependent signaling, causing STAT1-mediated suppression of Ulk1 transcription and impairment of microglial autophagy. Conditional microglial Stat1 knockout restores ULK1 expression and autophagy.","method":"Luciferase reporter assay (Ulk1 promoter), Stat1 knockdown and overexpression, conditional microglial Stat1-KO mice, TLR4 dependency analysis, autophagy flux measurements","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay, Stat1 KO/KD, in vivo conditional knockout; single lab with multiple methods","pmids":["39462396"],"is_preprint":false},{"year":2023,"finding":"STAT1 is phosphorylated and activated by MST4 kinase in macrophages; MST4 silencing directly inhibits STAT1 phosphorylation, which is essential for M1 macrophage polarization. Macrophage-specific Mst4 knockout in an ITP mouse model reduces M1 macrophage numbers and attenuates thrombocytopenia.","method":"Co-immunoprecipitation, mass spectrometry, phosphoproteomics, RNA-seq, Mst4 conditional knockout mice, macrophage M1 polarization assays","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP/MS identifying MST4-STAT1 interaction, phosphoproteomics, in vivo conditional KO; single lab","pmids":["37833401"],"is_preprint":false},{"year":2018,"finding":"IRF1 promotes STAT1 phosphorylation at Tyr701 and subsequent GAS-element DNA binding through an indirect mechanism requiring IRF1 transactivation domain-dependent gene products (not direct IRF1-STAT1 interaction). IRF1-induced STAT1 activation is not blocked by IFN-beta or IFN-gamma antibodies, suggesting a novel cytokine mediates the effect. IRF1 deficiency reduces IFN-gamma-induced STAT1 phosphorylation persistence, establishing a positive feedback loop.","method":"Transient IRF1 overexpression in HEK293 cells, GAS-reporter assay, JAK1 phosphorylation analysis, IRF1-knockout cells (CRISPR), IRF1 complementation","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout plus complementation, reporter assay; indirect mechanism (no direct IRF1-STAT1 binding detected); single lab","pmids":["29893425"],"is_preprint":false},{"year":2024,"finding":"PRMT6 and STAT1 interact and synergistically regulate transcription of ACSL1. PRMT6 downregulation in diabetic nephropathy allows STAT1 to drive increased ACSL1 expression, promoting lipid peroxidation and ferroptosis in kidney cells. STAT1-specific inhibitor fludarabine delays DN progression in mouse models.","method":"Co-immunoprecipitation (PRMT6-STAT1), chromatin immunoprecipitation (STAT1 at ACSL1 promoter), PRMT6-/- mice, lipidomic analysis","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ChIP, genetic knockout, in vivo model; single lab","pmids":["39134684"],"is_preprint":false},{"year":2020,"finding":"STAT1 functions as a transcriptional suppressor of HIF1A by binding to the HIF1A promoter. Ablation of ATG7 upregulates STAT1 expression (via a ZNF148-dependent autophagy-independent mechanism), increases STAT1 binding to the HIF1A promoter, and suppresses HIF1A expression, thereby inhibiting angiogenesis.","method":"Chromatin immunoprecipitation (STAT1 binding HIF1A promoter), endothelial-specific Atg7 KO mice, fludarabine STAT1 inhibition, tube formation assay","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating STAT1 binding to HIF1A promoter, genetic KO, in vivo rescue; single lab","pmids":["36300763"],"is_preprint":false},{"year":2021,"finding":"Bcl6 directly binds the Stat1 promoter (demonstrated by ChIP) and transcriptionally represses Stat1 expression in osteoblasts. Loss of Bcl6 elevates Stat1 mRNA and protein, which attenuates nuclear translocation of Runx2, inhibiting osteoblast differentiation. Double knockout of Bcl6 and Stat1 rescues the bone phenotype of Bcl6-deficient mice.","method":"Chromatin immunoprecipitation (Bcl6 at Stat1 promoter), Bcl6-/- x Stat1-/- double-knockout mice, osteoblast differentiation assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, genetic epistasis in double-KO mice; single lab; establishes Bcl6-STAT1-Runx2 axis","pmids":["25597995"],"is_preprint":false},{"year":2020,"finding":"S-glutathionylation of STAT1 (oxidative modification) induced by oxidative stress causes aberrant hyperactivation of STAT1 signaling in microglia, contributing to neuroinflammation under hypoxia. Both phosphorylation and S-glutathionylation of STAT1 are induced by hypoxia and drive M1 microglia activation.","method":"S-glutathionylation assay, STAT1 silencing, hypoxia model in BV2 cells, M1 phenotype markers","journal":"Archives of biochemistry and biophysics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, cell line model only, S-glutathionylation detection without site mapping or mutagenesis validation","pmids":["31121156"],"is_preprint":false},{"year":2017,"finding":"STAT1 occupies a conserved binding element at IRF1 and STAT1 co-regulated ISG enhancers. IRF1 binds proximal or distant ISG sites more frequently than STAT1, and STAT1 almost always binds together with IRF1, while most IRF1 binding events are isolated. Dual STAT1+IRF1 binding at remote or proximal enhancers distinguishes IFNgamma-responsive from cell-type-resistant ISGs.","method":"ChIP-seq (STAT1 and IRF1 binding in multiple cell types), in vitro EMSA with SNP variants, in vivo ChIP validation","journal":"BMC molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with in vitro and in vivo validation; multiple cell types; single lab","pmids":["28274199"],"is_preprint":false},{"year":2020,"finding":"STAT1 directly binds the upstream region (-29 to -12 bp) of the S1PR1 promoter and stimulates S1PR1 transcription. STAT1 knockdown reduces S1PR1 mRNA and protein; STAT1 overexpression increases S1PR1 levels. IFN-gamma activation of STAT1 increases S1PR1 expression.","method":"EMSA, chromatin immunoprecipitation, promoter-deletion reporter assay, STAT1 knockdown and overexpression","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus ChIP plus reporter assay; single lab","pmids":["32006593"],"is_preprint":false}],"current_model":"STAT1 is a latent cytoplasmic transcription factor that, upon IFN (and other cytokine) stimulation, is phosphorylated on Tyr701 by JAK1 (or Syk in viral infection), forming homodimers (GAS-binding) or heterodimers/ISGF3 with STAT2 and IRF9 (ISRE-binding) via SH2–phosphotyrosine interactions; these active dimers undergo importin-dependent nuclear import, bind DNA to drive ISG transcription, and are recycled to the cytoplasm after TC45-mediated dephosphorylation once released from DNA. A multilayered post-translational regulatory code—including Ser727 phosphorylation (by PKCδ, p38), acetylation at Lys410/413 (by CBP, reversed by HDAC3), K63-linked ubiquitination (by RNF220 at K110, by NKLAM), linear ubiquitination (by LUBAC at K511/K652, removed by OTULIN), ADP-ribosylation (by PARP14, counteracted by PARP9), SUMOylation (at K703), and Thr748 phosphorylation (by IKK, LPS-dependent)—fine-tunes STAT1 activation, nuclear retention, DNA binding, and interactions with NF-κB p65, cyclin D1/CDK4, importin α5, and PIAS1, enabling STAT1 to control ISG expression, cell-cycle arrest, autophagy, apoptosis, osteoblast differentiation, and inflammatory gene programs."},"narrative":{"mechanistic_narrative":"STAT1 is a latent cytoplasmic transcription factor that converts cytokine receptor engagement into interferon-stimulated gene (ISG) transcription, governing antiviral defense, cell-cycle arrest, autophagy, apoptosis, and inflammatory gene programs [PMID:7690989, PMID:1502203, PMID:1502204]. In response to IFN-gamma, JAK1 phosphorylates STAT1 on a single residue, Tyr701, which is required for homodimer formation, nuclear translocation, DNA binding, and gene activation; the C-terminal transactivation domain is independently essential for transcription [PMID:7690989, PMID:8114747]. Dimerization occurs through reciprocal SH2-domain recognition of the partner's phosphotyrosine, and only the phosphorylated dimer binds DNA [PMID:7510216], while in the IFN-alpha response phosphorylated STAT1 assembles with STAT2 and a DNA-binding subunit into the ISGF3 complex that drives ISG expression [PMID:1502203, PMID:1502204, PMID:8197134]. Crystallographic and biophysical analysis show that unphosphorylated STAT1 is already dimeric through N-domain contacts and interconverts between antiparallel and parallel orientations, and that the SH2 domain docks onto the IFN-gamma receptor phosphopeptide [PMID:15780933]. Nuclear accumulation proceeds in two steps—importin-dependent import followed by DNA-binding-mediated retention—and recycling requires tyrosine dephosphorylation and CRM1-dependent export, with continuous nucleocytoplasmic cycling sustained by ongoing kinase activity [PMID:12923054, PMID:12915721]. A dense post-translational code tunes this cycle: Ser727 phosphorylation by PKCdelta links STAT1 to DNA-damage-induced apoptosis [PMID:15322115]; acetylation at Lys410/413 by CBP (reversed by HDAC3) recruits the phosphatase TC45 to drive latency and redirects STAT1 to antagonize NF-kappaB p65 [PMID:16481475, PMID:19171783]; K63-linked ubiquitination by RNF220 at Lys110 and by NKLAM promotes JAK1 association and DNA binding [PMID:32814877, PMID:27570112]; linear ubiquitination by LUBAC at Lys511/Lys652, removed by OTULIN, restrains receptor engagement [PMID:32123171]; and PARP14-mediated ADP-ribosylation, antagonized by PARP9, suppresses phosphorylation [PMID:27796300]. Beyond canonical JAK signaling, STAT1 is activated by Syk downstream of RIG-I/MAVS during viral infection [PMID:33472080] and by IKK-phosphorylation at Thr748, an IFN-independent inflammatory switch [PMID:38621137]. As a transcription factor STAT1 directly activates targets including NAMPT, S1PR1, and HK2 and represses ULK1, FOXM1, and HIF1A, thereby controlling macrophage metabolism, autophagy, and angiogenesis [PMID:33976173, PMID:28011640, PMID:36300763, PMID:32006593], and it acts independently of IFN receptors as a cytoplasmic attenuator of Runx2 in osteoblasts and as a downstream effector of PDGFRbeta-driven autoinflammation [PMID:15546140, PMID:28924035]. Gain-of-function disease variants act by elevating total STAT1 protein and thus peak phospho-STAT1 rather than by impairing dephosphorylation [PMID:31354696].","teleology":[{"year":1992,"claim":"Established that STAT1 is a physical component of a cytokine-activated nuclear transcription complex, defining it as a signal-dependent transcription factor rather than a constitutive regulator.","evidence":"Protein purification, peptide sequencing, and cDNA cloning of the ISGF-3 complex activated by IFN-alpha","pmids":["1502203","1502204"],"confidence":"High","gaps":["Did not define the activating modification","Stoichiometry and assembly order of ISGF3 subunits unresolved at this stage"]},{"year":1993,"claim":"Pinpointed the single activating event—Tyr701 phosphorylation—and separated activation from transcriptional output by showing the C-terminal transactivation domain is independently required.","evidence":"Site-directed mutagenesis, phosphorylation mapping, and reporter assays comparing full-length and C-terminally truncated isoforms in IFN-gamma response","pmids":["7690989"],"confidence":"High","gaps":["Did not identify the kinase responsible","Dimerization mechanism not yet defined"]},{"year":1994,"claim":"Defined the dimerization mechanism and upstream kinase, showing phospho-Tyr701 drives SH2-mediated homodimer formation and that JAK1 is the kinase required for STAT1 activation by both type I and II IFNs.","evidence":"Dissociation/reassociation biochemistry with SH2 mutants and gel-shift assays; JAK1-deficient mutant cell complementation","pmids":["7510216","8114747","8197134"],"confidence":"High","gaps":["Structural basis of the SH2-phosphopeptide docking not yet resolved","Did not address non-IFN receptor inputs"]},{"year":1994,"claim":"Showed STAT1 activation is not restricted to interferons, extending it to growth hormone and GPCR (angiotensin II/AT1A) signaling and broadening its physiological scope.","evidence":"In vivo GH liver model and AT1A receptor activation with nuclear fractionation, EMSA, and tyrosine kinase inhibitor studies","pmids":["7510676","7527386"],"confidence":"Medium","gaps":["Kinases coupling GH/GPCR receptors to STAT1 not fully defined","Physiological gene targets in these contexts not mapped"]},{"year":1998,"claim":"Identified negative regulation and cooperative DNA recognition, with PIAS1 blocking activated STAT1 DNA binding and N-domain contacts driving heterotetramer formation on tandem GAS/ISRE sites.","evidence":"Reciprocal co-IP, EMSA with Tyr701 and N-terminal deletion mutants; caspase cleavage abolishing signaling during apoptosis","pmids":["9724754","9865492","9535846"],"confidence":"Medium","gaps":["Whether PIAS1 acts catalytically or stoichiometrically not defined","In vivo significance of heterotetramers not established"]},{"year":2003,"claim":"Resolved the nuclear trafficking cycle: import plus DNA-binding-mediated retention, dephosphorylation-dependent CRM1 export, and energy-independent diffusion to the nuclear pore sustained by continuous kinase activity.","evidence":"Microinjection of recombinant STAT1, FRAP/FLIP live imaging of STAT1-GFP, kinase/phosphatase inhibitors, and domain mapping","pmids":["12923054","11350940","12915721"],"confidence":"High","gaps":["Identity of the nuclear phosphatase not yet established here","Import receptor identity addressed only later"]},{"year":2005,"claim":"Provided the structural model of STAT1, showing unphosphorylated dimers held by N-domain contacts and interconverting antiparallel/parallel conformations with the SH2 domain docked on the IFN-gamma receptor peptide.","evidence":"X-ray crystallography at 3.0 A with analytical ultracentrifugation, light scattering, and co-IP","pmids":["15780933"],"confidence":"High","gaps":["Structure of the phosphorylated DNA-bound dimer not in this study","Full-length C-terminal transactivation domain not resolved"]},{"year":2005,"claim":"Revealed an IFN-independent cytoplasmic role, with STAT1 attenuating Runx2 to restrain osteoblast differentiation and bone mass.","evidence":"Stat1-knockout mice with osteoblast differentiation and Runx2 nuclear translocation assays","pmids":["15546140"],"confidence":"Medium","gaps":["Molecular basis of cytoplasmic Runx2 sequestration not defined","Whether STAT1 modifications regulate this function unknown"]},{"year":2006,"claim":"Opened the post-translational regulatory layer by identifying acetylation (Lys410/413, CBP-dependent) as a modification that reroutes STAT1 to antagonize NF-kappaB p65 and SUMOylation at Lys703 as a modest DNA-binding/retention modulator.","evidence":"Acetylation- and SUMO-site mutants, co-IP, HAT/HDAC modulation, and in vitro SUMOylation with complementation in STAT1-/- cells","pmids":["16481475","16857984"],"confidence":"Medium","gaps":["In vivo significance of K703 SUMOylation appears limited","Crosstalk between acetylation and phosphorylation not yet defined here"]},{"year":2009,"claim":"Defined a phosphorylation-acetylation switch, showing CBP acetylation recruits the phosphatase TC45 to dephosphorylate STAT1 and impose latency, reversed by HDAC3.","evidence":"Acetylation/phosphorylation mutants, HAT/HDAC modulation, co-IP, and reporter assays reconstituting the switch","pmids":["19171783"],"confidence":"High","gaps":["Whether the switch operates at all receptors not tested","Spatial coordination of TC45 recruitment unresolved"]},{"year":2010,"claim":"Connected STAT1 to cell-cycle control via direct cyclin D1/CDK4 binding and Ser727-dependent proteasomal cyclin D1 degradation, mediating IFN-gamma-induced arrest.","evidence":"Co-IP, proteasome inhibition, and Ser727/Tyr701 mutant analysis in STAT1-deficient cells","pmids":["21084836"],"confidence":"Medium","gaps":["Whether degradation is direct or transcriptionally mediated not resolved","Single lab"]},{"year":2014,"claim":"Showed STAT1 governs inflammatory output beyond ISG transcription by promoting HMGB1 NLS hyperacetylation and nucleocytoplasmic translocation.","evidence":"Mass spectrometry acetylation mapping, JAK inhibition, STAT1 knockout, and subcellular fractionation","pmids":["24469805"],"confidence":"High","gaps":["Acetyltransferase linking STAT1 to HMGB1 not identified","Direct vs indirect mechanism unresolved"]},{"year":2016,"claim":"Established ubiquitin and ADP-ribosylation control of STAT1, with NKLAM K63-ubiquitination required for DNA binding, PARP14 ADP-ribosylation suppressing phosphorylation (antagonized by PARP9), and STAT1 directly driving NAMPT for macrophage metabolic reprogramming.","evidence":"K63-specific ubiquitination assays in NKLAM-KO macrophages; ADP-ribosylation with PARP9/14 silencing and site mutagenesis; ChIP with NRE1 disruption mouse","pmids":["27570112","27796300","33976173"],"confidence":"High","gaps":["How K63 ubiquitination mechanistically enables DNA binding unclear","Interplay among competing modifications not integrated"]},{"year":2016,"claim":"Identified STAT1 as a transcriptional repressor of autophagy via direct suppression of ULK1, integrating STAT1 with mTOR-regulated autophagic flux.","evidence":"ChIP, promoter reporter mutagenesis, and STAT1-deficient cells and mice with autophagic flux measurement","pmids":["28011640"],"confidence":"High","gaps":["Whether ULK1 repression requires Tyr701 vs Ser727 not defined","Cofactors at the ULK1 promoter unknown"]},{"year":2017,"claim":"Defined STAT1-IRF1 enhancer co-occupancy as a determinant of ISG responsiveness and revealed an IFN-receptor-independent role for STAT1 downstream of PDGFRbeta in autoinflammation and tissue wasting.","evidence":"ChIP-seq of STAT1/IRF1 across cell types; genetic epistasis of Stat1-/- with Pdgfrb gain-of-function and Ifnar1/Ifngr1 knockout crosses","pmids":["28274199","28924035"],"confidence":"High","gaps":["How PDGFRbeta activates STAT1 without IFN receptors not defined","Determinants of STAT1/IRF1 co-binding selectivity unresolved"]},{"year":2019,"claim":"Expanded regulators and targets: PHLPP1 dephosphorylates nuclear Ser727 to limit promoter residency, IRF1 sustains STAT1 Tyr701 phosphorylation via an indirect feedback loop, and STAT1 represses FOXM1 to sensitize tumor cells.","evidence":"PHLPP1-KO mice with ChIP; IRF1-KO/complementation with GAS reporters; ChIP and luciferase at the FOXM1 promoter","pmids":["31408005","29893425","30782607"],"confidence":"Medium","gaps":["Cytokine mediating IRF1-driven STAT1 activation not identified","PHLPP1 substrate selectivity within the nucleus not fully mapped"]},{"year":2019,"claim":"Reframed the basis of STAT1 gain-of-function disease, showing elevated total STAT1 protein—not impaired dephosphorylation—drives high peak phospho-STAT1.","evidence":"Flow cytometry, immunoblot, qRT-PCR, cycloheximide chase, and ruxolitinib dephosphorylation kinetics in patient PBMCs","pmids":["31354696"],"confidence":"Medium","gaps":["Mechanism elevating STAT1 mRNA in patients not defined","Single patient-cell study"]},{"year":2020,"claim":"Resolved layered ubiquitin and conformational control of STAT1 activation, with LUBAC linear ubiquitination (OTULIN-reversed) restraining receptor binding, RNF220 K63-ubiquitination at Lys110 promoting JAK1 association, and IKK-epsilon phosphorylation of STAT2 disrupting the inactive U-STAT1-U-STAT2 dimer to enable ISGF3 assembly.","evidence":"Linear/K63 ubiquitination assays with site mutagenesis, DUB/E3 manipulation, receptor-binding and JAK1 interaction assays, EM structure, and T403A/HOIL-1L mouse models","pmids":["32123171","32814877","32759968"],"confidence":"High","gaps":["How competing ubiquitin marks are temporally coordinated unresolved","Stoichiometry of the U-STAT1-U-STAT2 pool unknown"]},{"year":2020,"claim":"Extended STAT1's transcriptional repertoire to angiogenesis and signaling regulation, repressing HIF1A and activating S1PR1, with additional oxidative S-glutathionylation reported to hyperactivate STAT1.","evidence":"ChIP/EMSA/reporter assays at HIF1A and S1PR1 promoters with knockdown/overexpression; S-glutathionylation assay in BV2 microglia","pmids":["36300763","32006593","31121156"],"confidence":"Medium","gaps":["S-glutathionylation site not mapped or validated by mutagenesis (Low-confidence)","Context-dependence of activation vs repression at different promoters unresolved"]},{"year":2021,"claim":"Identified cytokine-independent activation and protein-level stabilization of STAT1, with Syk phosphorylating Tyr701 downstream of RIG-I/MAVS during influenza and CCT6A protecting STAT1 from proteasomal degradation to drive HK2-dependent glycolysis.","evidence":"Syk deletion and STAT1-Y701F knockin mice; co-IP/MS, ChIP, and ubiquitination assays with CCT6A silencing","pmids":["33472080","38750462"],"confidence":"High","gaps":["Whether Syk acts at the receptor or in the cytosol not fully defined","CCT6A finding from a single lab"]},{"year":2022,"claim":"Revealed cytoplasmic gating of STAT1 nuclear entry, with ADAP competing against importin alpha5 for STAT1 binding to restrain nuclear translocation and FcgammaR-driven phagocytosis.","evidence":"Co-IP of ADAP-STAT1-importin alpha5, ADAP-/- mice, nuclear translocation and FcgammaR expression assays, and pharmacological STAT1 inhibition","pmids":["35637282"],"confidence":"Medium","gaps":["Whether ADAP regulation is modification-dependent unknown","Single lab"]},{"year":2023,"claim":"Connected STAT1 to transcriptional machinery recruitment and additional disease contexts, with DHX9 bridging STAT1 to RNA Pol II at ISG promoters, MST4 phosphorylating STAT1 for M1 polarization, and STAT1 repressing microglial Ulk1 in synucleinopathy.","evidence":"Co-IP and ChIP with conditional DHX9/STAT1 double-KO mice; co-IP/MS and Mst4 conditional KO; luciferase, KO/KD, and conditional microglial Stat1-KO with TLR4 dependency","pmids":["36735791","37833401","39462396"],"confidence":"Medium","gaps":["Direct vs scaffold role of DHX9 in Pol II loading not separated","Each finding from a single lab"]},{"year":2024,"claim":"Defined an IFN-independent inflammatory phosphorylation switch and further metabolic/disease roles, with IKK phosphorylating STAT1 at Thr748 to bias macrophages toward inflammation and STAT1 partnering with PRMT6 to drive ACSL1-dependent ferroptosis.","evidence":"T748A knockin mice with IKK kinase assay and LPS lethality model; co-IP and ChIP with PRMT6-/- mice and lipidomics","pmids":["38621137","39134684"],"confidence":"High","gaps":["How Thr748 phosphorylation mechanistically suppresses IFN output unresolved","PRMT6-STAT1 finding from a single lab"]},{"year":null,"claim":"How the dense array of competing post-translational modifications, cytoplasmic gating factors, and alternative kinases is integrated to set STAT1 activity in a given cell and stimulus remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified quantitative model of PTM crosstalk on STAT1","Stimulus- and cell-type-specific selection between JAK1, Syk, IKK, MST4, and PKCdelta inputs not defined","Determinants directing STAT1 to activate vs repress specific target promoters unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,27,28,29,41,45]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,7,24,26,44]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[12,19]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,7,11,36]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,7,9,25]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[25,7]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,21,23,27,33]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,27,28,29,41,45]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,22,23,32,39]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[14]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[28,37]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[21,22,26,20,35]}],"complexes":["ISGF3"],"partners":["STAT2","JAK1","PIAS1","CBP","RNF220","DHX9","PARP14","IMPORTIN ALPHA5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P42224","full_name":"Signal transducer and activator of transcription 1-alpha/beta","aliases":["Transcription factor ISGF-3 components p91/p84"],"length_aa":750,"mass_kda":87.3,"function":"Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors (PubMed:12764129, PubMed:12855578, PubMed:15322115, PubMed:23940278, PubMed:34508746, PubMed:35568036, PubMed:9724754). Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus (PubMed:28753426, PubMed:35568036). ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state (PubMed:28753426, PubMed:35568036). In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated (PubMed:26479788). It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state (PubMed:8156998). Becomes activated in response to KITLG/SCF and KIT signaling (PubMed:15526160). May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:19088846). Following bacterial lipopolysaccharide (LPS)-induced TLR4 endocytosis, phosphorylated at Thr-749 by IKBKB which promotes binding of STAT1 to the 5'-TTTGAGGC-3' sequence in the ARID5A promoter, resulting in transcriptional activation of ARID5A and subsequent ARID5A-mediated stabilization of IL6 (PubMed:32209697). Phosphorylation at Thr-749 also promotes binding of STAT1 to the 5'-TTTGAGTC-3' sequence in the IL12B promoter and activation of IL12B transcription (PubMed:32209697). Involved in food tolerance in small intestine: associates with the Gasdermin-D, p13 cleavage product (13 kDa GSDMD) and promotes transcription of CIITA, inducing type 1 regulatory T (Tr1) cells in upper small intestine (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P42224/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/STAT1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/STAT1","total_profiled":1310},"omim":[{"mim_id":"621405","title":"IMMUNODEFICIENCY 134 (EPSTEIN-BARR VIRUS-SPECIFIC); IMD134","url":"https://www.omim.org/entry/621405"},{"mim_id":"621374","title":"SERINE/THREONINE/TYROSINE-INTERACTING PROTEIN-LIKE 2; STYXL2","url":"https://www.omim.org/entry/621374"},{"mim_id":"621173","title":"G PROTEIN-COUPLED RECEPTOR 146; GPR146","url":"https://www.omim.org/entry/621173"},{"mim_id":"620868","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3C; ARID3C","url":"https://www.omim.org/entry/620868"},{"mim_id":"620668","title":"IMMUNODEFICIENCY 117; IMD117","url":"https://www.omim.org/entry/620668"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/STAT1"},"hgnc":{"alias_symbol":["STAT91","ISGF-3"],"prev_symbol":[]},"alphafold":{"accession":"P42224","domains":[{"cath_id":"1.10.532.10","chopping":"2-96","consensus_level":"high","plddt":92.9377,"start":2,"end":96},{"cath_id":"1.20.1050.20","chopping":"140-180_191-313","consensus_level":"high","plddt":94.6104,"start":140,"end":313},{"cath_id":"2.60.40.630","chopping":"325-412_424-459","consensus_level":"high","plddt":92.7935,"start":325,"end":459},{"cath_id":"3.30.505.10","chopping":"582-683_702-739","consensus_level":"medium","plddt":80.5386,"start":582,"end":739}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42224","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42224-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42224-F1-predicted_aligned_error_v6.png","plddt_mean":87.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=STAT1","jax_strain_url":"https://www.jax.org/strain/search?query=STAT1"},"sequence":{"accession":"P42224","fasta_url":"https://rest.uniprot.org/uniprotkb/P42224.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42224/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42224"}},"corpus_meta":[{"pmid":"7690989","id":"PMC_7690989","title":"A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7690989","citation_count":744,"is_preprint":false},{"pmid":"7510216","id":"PMC_7510216","title":"Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7510216","citation_count":725,"is_preprint":false},{"pmid":"1502203","id":"PMC_1502203","title":"Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1502203","citation_count":602,"is_preprint":false},{"pmid":"9724754","id":"PMC_9724754","title":"Inhibition of Stat1-mediated gene activation by PIAS1.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9724754","citation_count":586,"is_preprint":false},{"pmid":"1502204","id":"PMC_1502204","title":"The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1502204","citation_count":490,"is_preprint":false},{"pmid":"24469805","id":"PMC_24469805","title":"JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24469805","citation_count":301,"is_preprint":false},{"pmid":"19171783","id":"PMC_19171783","title":"A phosphorylation-acetylation switch regulates STAT1 signaling.","date":"2009","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/19171783","citation_count":243,"is_preprint":false},{"pmid":"15780933","id":"PMC_15780933","title":"Structural bases of unphosphorylated STAT1 association and receptor binding.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15780933","citation_count":238,"is_preprint":false},{"pmid":"27796300","id":"PMC_27796300","title":"PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27796300","citation_count":238,"is_preprint":false},{"pmid":"17085014","id":"PMC_17085014","title":"STAT1 as a key modulator of cell death.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/17085014","citation_count":237,"is_preprint":false},{"pmid":"26631912","id":"PMC_26631912","title":"The good and the bad faces of STAT1 in solid tumours.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/26631912","citation_count":227,"is_preprint":false},{"pmid":"24058752","id":"PMC_24058752","title":"STAT1 and STAT3 in tumorigenesis: A matter of balance.","date":"2012","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24058752","citation_count":224,"is_preprint":false},{"pmid":"16481475","id":"PMC_16481475","title":"Acetylation of Stat1 modulates NF-kappaB activity.","date":"2006","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16481475","citation_count":196,"is_preprint":false},{"pmid":"18620071","id":"PMC_18620071","title":"Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling.","date":"2008","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18620071","citation_count":192,"is_preprint":false},{"pmid":"11034357","id":"PMC_11034357","title":"Distinct requirements for IFNs and STAT1 in NK cell function.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11034357","citation_count":170,"is_preprint":false},{"pmid":"32987855","id":"PMC_32987855","title":"Redox Regulation of STAT1 and STAT3 Signaling.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32987855","citation_count":168,"is_preprint":false},{"pmid":"7527386","id":"PMC_7527386","title":"Angiotensin II stimulates sis-inducing factor-like DNA binding activity. Evidence that the AT1A receptor activates transcription factor-Stat91 and/or a related protein.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7527386","citation_count":150,"is_preprint":false},{"pmid":"24280128","id":"PMC_24280128","title":"NF-κB and STAT1 control CXCL1 and CXCL2 gene transcription.","date":"2013","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24280128","citation_count":149,"is_preprint":false},{"pmid":"8197134","id":"PMC_8197134","title":"Transcription factor ISGF-3 formation requires phosphorylated Stat91 protein, but Stat113 protein is phosphorylated independently of Stat91 protein.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8197134","citation_count":138,"is_preprint":false},{"pmid":"31121156","id":"PMC_31121156","title":"STAT1 drives M1 microglia activation and neuroinflammation under hypoxia.","date":"2019","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/31121156","citation_count":132,"is_preprint":false},{"pmid":"12923054","id":"PMC_12923054","title":"DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1.","date":"2003","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/12923054","citation_count":128,"is_preprint":false},{"pmid":"16243709","id":"PMC_16243709","title":"Opposing actions of STAT-1 and STAT-3.","date":"2005","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/16243709","citation_count":128,"is_preprint":false},{"pmid":"28950072","id":"PMC_28950072","title":"STAT1 in cancer: friend or foe?","date":"2017","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28950072","citation_count":127,"is_preprint":false},{"pmid":"20159032","id":"PMC_20159032","title":"STAT1 and pathogens, not a friendly relationship.","date":"2010","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/20159032","citation_count":117,"is_preprint":false},{"pmid":"7510676","id":"PMC_7510676","title":"Rapid changes in nuclear protein tyrosine phosphorylation after growth hormone treatment in vivo. Identification of phosphorylated mitogen-activated protein kinase and STAT91.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7510676","citation_count":117,"is_preprint":false},{"pmid":"19503789","id":"PMC_19503789","title":"STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19503789","citation_count":107,"is_preprint":false},{"pmid":"32123171","id":"PMC_32123171","title":"Regulation of the linear ubiquitination of STAT1 controls antiviral interferon signaling.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32123171","citation_count":101,"is_preprint":false},{"pmid":"10851049","id":"PMC_10851049","title":"Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851049","citation_count":91,"is_preprint":false},{"pmid":"9535846","id":"PMC_9535846","title":"STAT1 is inactivated by a caspase.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9535846","citation_count":90,"is_preprint":false},{"pmid":"24058806","id":"PMC_24058806","title":"The tumor suppressor function of STAT1 in breast cancer.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24058806","citation_count":88,"is_preprint":false},{"pmid":"19879327","id":"PMC_19879327","title":"Phosphorylation-acetylation switch in the regulation of STAT1 signaling.","date":"2009","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19879327","citation_count":86,"is_preprint":false},{"pmid":"23013371","id":"PMC_23013371","title":"STAT1 expression and activation is increased in lesional psoriatic skin.","date":"2013","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23013371","citation_count":81,"is_preprint":false},{"pmid":"16449678","id":"PMC_16449678","title":"Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.","date":"2006","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/16449678","citation_count":74,"is_preprint":false},{"pmid":"21084836","id":"PMC_21084836","title":"STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21084836","citation_count":72,"is_preprint":false},{"pmid":"11350940","id":"PMC_11350940","title":"STAT1 from the cell membrane to the DNA.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11350940","citation_count":69,"is_preprint":false},{"pmid":"37611494","id":"PMC_37611494","title":"Ferroptosis triggered by STAT1- IRF1-ACSL4 pathway was involved in radiation-induced intestinal injury.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37611494","citation_count":68,"is_preprint":false},{"pmid":"35656941","id":"PMC_35656941","title":"Unique aspects of IFN-γ/STAT1 signaling in neurons.","date":"2022","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35656941","citation_count":61,"is_preprint":false},{"pmid":"12967644","id":"PMC_12967644","title":"IFNalpha regulates NK cell cytotoxicity through STAT1 pathway.","date":"2003","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/12967644","citation_count":58,"is_preprint":false},{"pmid":"31354696","id":"PMC_31354696","title":"STAT1 Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal Dephosphorylation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31354696","citation_count":57,"is_preprint":false},{"pmid":"12915721","id":"PMC_12915721","title":"The ins and outs of STAT1 nuclear transport.","date":"2003","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/12915721","citation_count":55,"is_preprint":false},{"pmid":"27862996","id":"PMC_27862996","title":"Tannic acid inhibits EGFR/STAT1/3 and enhances p38/STAT1 signalling axis in breast cancer cells.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27862996","citation_count":55,"is_preprint":false},{"pmid":"17328836","id":"PMC_17328836","title":"Transcription protein STAT1: biology and relation to cancer.","date":"2007","source":"Folia biologica","url":"https://pubmed.ncbi.nlm.nih.gov/17328836","citation_count":53,"is_preprint":false},{"pmid":"18523269","id":"PMC_18523269","title":"IFN-gamma and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18523269","citation_count":53,"is_preprint":false},{"pmid":"24131713","id":"PMC_24131713","title":"Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/24131713","citation_count":53,"is_preprint":false},{"pmid":"33472080","id":"PMC_33472080","title":"Critical role of Syk-dependent STAT1 activation in innate antiviral immunity.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33472080","citation_count":48,"is_preprint":false},{"pmid":"15322115","id":"PMC_15322115","title":"Protein kinase Cdelta regulates apoptosis via activation of STAT1.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15322115","citation_count":47,"is_preprint":false},{"pmid":"33976173","id":"PMC_33976173","title":"A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33976173","citation_count":46,"is_preprint":false},{"pmid":"29893425","id":"PMC_29893425","title":"IRF1 supports DNA binding of STAT1 by promoting its phosphorylation.","date":"2018","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29893425","citation_count":45,"is_preprint":false},{"pmid":"32759968","id":"PMC_32759968","title":"A virus-induced conformational switch of STAT1-STAT2 dimers boosts antiviral defenses.","date":"2020","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/32759968","citation_count":43,"is_preprint":false},{"pmid":"30782607","id":"PMC_30782607","title":"STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/30782607","citation_count":41,"is_preprint":false},{"pmid":"37833401","id":"PMC_37833401","title":"MST4 kinase regulates immune thrombocytopenia by phosphorylating STAT1-mediated M1 polarization of macrophages.","date":"2023","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37833401","citation_count":40,"is_preprint":false},{"pmid":"16857984","id":"PMC_16857984","title":"Stat1 and SUMO modification.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16857984","citation_count":40,"is_preprint":false},{"pmid":"39134684","id":"PMC_39134684","title":"The PRMT6/STAT1/ACSL1 axis promotes ferroptosis in diabetic nephropathy.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/39134684","citation_count":39,"is_preprint":false},{"pmid":"28924035","id":"PMC_28924035","title":"STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/28924035","citation_count":39,"is_preprint":false},{"pmid":"23588992","id":"PMC_23588992","title":"STAT1 negatively regulates hepatocellular carcinoma cell proliferation.","date":"2013","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23588992","citation_count":39,"is_preprint":false},{"pmid":"28274199","id":"PMC_28274199","title":"Properties of STAT1 and IRF1 enhancers and the influence of SNPs.","date":"2017","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28274199","citation_count":38,"is_preprint":false},{"pmid":"16380292","id":"PMC_16380292","title":"IFNgammaR2 trafficking tunes IFNgamma-STAT1 signaling in T lymphocytes.","date":"2005","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16380292","citation_count":38,"is_preprint":false},{"pmid":"28011640","id":"PMC_28011640","title":"Regulation of ULK1 Expression and Autophagy by STAT1.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28011640","citation_count":37,"is_preprint":false},{"pmid":"22262126","id":"PMC_22262126","title":"Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy.","date":"2012","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22262126","citation_count":37,"is_preprint":false},{"pmid":"34825733","id":"PMC_34825733","title":"Mettl3 promotes oxLDL-mediated inflammation through activating STAT1 signaling.","date":"2021","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/34825733","citation_count":36,"is_preprint":false},{"pmid":"32503893","id":"PMC_32503893","title":"Upregulated PKM2 in Macrophages Exacerbates Experimental Arthritis via STAT1 Signaling.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32503893","citation_count":36,"is_preprint":false},{"pmid":"15546140","id":"PMC_15546140","title":"Stat1-mediated cytoplasmic attenuation in osteoimmunology.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15546140","citation_count":35,"is_preprint":false},{"pmid":"12954221","id":"PMC_12954221","title":"The PKR kinase promoter binds both Sp1 and Sp3, but only Sp3 functions as part of the interferon-inducible complex with ISGF-3 proteins.","date":"2003","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/12954221","citation_count":33,"is_preprint":false},{"pmid":"32994273","id":"PMC_32994273","title":"STAT1 Dissociates Adipose Tissue Inflammation From Insulin Sensitivity in Obesity.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/32994273","citation_count":33,"is_preprint":false},{"pmid":"9865492","id":"PMC_9865492","title":"Cooperative binding of Stat1-2 heterodimers and ISGF3 to tandem DNA elements.","date":"1998","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/9865492","citation_count":33,"is_preprint":false},{"pmid":"32814877","id":"PMC_32814877","title":"RNF220 mediates K63-linked polyubiquitination of STAT1 and promotes host defense.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/32814877","citation_count":32,"is_preprint":false},{"pmid":"24728078","id":"PMC_24728078","title":"Increased STAT1 signaling in endocrine-resistant breast cancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24728078","citation_count":32,"is_preprint":false},{"pmid":"31329047","id":"PMC_31329047","title":"Activation of the STAT1 Pathway Accelerates Periodontitis in Nos3 Mice.","date":"2019","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/31329047","citation_count":30,"is_preprint":false},{"pmid":"28348106","id":"PMC_28348106","title":"Unphosphorylated STAT1 represses apoptosis in macrophages during Mycobacteriumtuberculosis infection.","date":"2017","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/28348106","citation_count":30,"is_preprint":false},{"pmid":"31408005","id":"PMC_31408005","title":"PHLPP1 counter-regulates STAT1-mediated inflammatory signaling.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31408005","citation_count":29,"is_preprint":false},{"pmid":"38750462","id":"PMC_38750462","title":"CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38750462","citation_count":29,"is_preprint":false},{"pmid":"36300763","id":"PMC_36300763","title":"Ablation of endothelial Atg7 inhibits ischemia-induced angiogenesis by upregulating Stat1 that suppresses Hif1a expression.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36300763","citation_count":28,"is_preprint":false},{"pmid":"36735791","id":"PMC_36735791","title":"Nucleic DHX9 cooperates with STAT1 to transcribe interferon-stimulated genes.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36735791","citation_count":28,"is_preprint":false},{"pmid":"34365659","id":"PMC_34365659","title":"CITED2 inhibits STAT1-IRF1 signaling and atherogenesis.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34365659","citation_count":27,"is_preprint":false},{"pmid":"36374433","id":"PMC_36374433","title":"Transcriptional expression of CXCL10 and STAT1 in lupus nephritis and the intervention effect of triptolide.","date":"2022","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/36374433","citation_count":25,"is_preprint":false},{"pmid":"28154246","id":"PMC_28154246","title":"Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3.","date":"2017","source":"Bioscience trends","url":"https://pubmed.ncbi.nlm.nih.gov/28154246","citation_count":25,"is_preprint":false},{"pmid":"28552376","id":"PMC_28552376","title":"Involvement of STAT1 in proliferation and invasiveness of trophoblastic cells.","date":"2017","source":"Reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/28552376","citation_count":25,"is_preprint":false},{"pmid":"25597995","id":"PMC_25597995","title":"Bcl6 promotes osteoblastogenesis through Stat1 inhibition.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25597995","citation_count":25,"is_preprint":false},{"pmid":"7529187","id":"PMC_7529187","title":"Induction of expression of interferon-stimulated gene factor-3 (ISGF-3) proteins by interferons.","date":"1995","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/7529187","citation_count":23,"is_preprint":false},{"pmid":"24069559","id":"PMC_24069559","title":"Computational models of the JAK1/2-STAT1 signaling.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24069559","citation_count":23,"is_preprint":false},{"pmid":"27570112","id":"PMC_27570112","title":"E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27570112","citation_count":23,"is_preprint":false},{"pmid":"34784299","id":"PMC_34784299","title":"CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34784299","citation_count":23,"is_preprint":false},{"pmid":"32903273","id":"PMC_32903273","title":"Lyssavirus P-protein selectively targets STAT3-STAT1 heterodimers to modulate cytokine signalling.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32903273","citation_count":22,"is_preprint":false},{"pmid":"35637282","id":"PMC_35637282","title":"ADAP restraint of STAT1 signaling regulates macrophage phagocytosis in immune thrombocytopenia.","date":"2022","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35637282","citation_count":22,"is_preprint":false},{"pmid":"34024027","id":"PMC_34024027","title":"circSVIL regulates bovine myoblast development by inhibiting STAT1 phosphorylation.","date":"2021","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34024027","citation_count":22,"is_preprint":false},{"pmid":"25116692","id":"PMC_25116692","title":"Analysis of STAT1 expression and biological activity reveals interferon-tau-dependent STAT1-regulated SOCS genes in the bovine endometrium.","date":"2016","source":"Reproduction, fertility, and development","url":"https://pubmed.ncbi.nlm.nih.gov/25116692","citation_count":22,"is_preprint":false},{"pmid":"30506884","id":"PMC_30506884","title":"RNF168 facilitates proliferation and invasion of esophageal carcinoma, possibly via stabilizing STAT1.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30506884","citation_count":21,"is_preprint":false},{"pmid":"8114747","id":"PMC_8114747","title":"Mutant cell lines unresponsive to alpha/beta and gamma interferon are defective in tyrosine phosphorylation of ISGF-3 alpha components.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8114747","citation_count":20,"is_preprint":false},{"pmid":"28431406","id":"PMC_28431406","title":"ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28431406","citation_count":19,"is_preprint":false},{"pmid":"38621137","id":"PMC_38621137","title":"Threonine phosphorylation of STAT1 restricts interferon signaling and promotes innate inflammatory responses.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38621137","citation_count":19,"is_preprint":false},{"pmid":"38287522","id":"PMC_38287522","title":"PVT1 promotes proliferation and macrophage immunosuppressive polarization through STAT1 and CX3CL1 regulation in glioblastoma multiforme.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38287522","citation_count":18,"is_preprint":false},{"pmid":"37556887","id":"PMC_37556887","title":"Prolonged STAT1 activation in neurons drives a pathological transcriptional response.","date":"2023","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/37556887","citation_count":18,"is_preprint":false},{"pmid":"37289831","id":"PMC_37289831","title":"Human cytomegalovirus UL138 interaction with USP1 activates STAT1 in infection.","date":"2023","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/37289831","citation_count":18,"is_preprint":false},{"pmid":"32175700","id":"PMC_32175700","title":"Fibroblast-specific Stat1 deletion enhances the myofibroblast phenotype during tissue repair.","date":"2020","source":"Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society","url":"https://pubmed.ncbi.nlm.nih.gov/32175700","citation_count":18,"is_preprint":false},{"pmid":"30456450","id":"PMC_30456450","title":"Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma.","date":"2018","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/30456450","citation_count":17,"is_preprint":false},{"pmid":"31671580","id":"PMC_31671580","title":"Early Pregnancy Induces Expression of STAT1, OAS1 and CXCL10 in Ovine Spleen.","date":"2019","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/31671580","citation_count":17,"is_preprint":false},{"pmid":"32774501","id":"PMC_32774501","title":"STAT1 expression and HPV16 viral load predict cervical lesion progression.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32774501","citation_count":16,"is_preprint":false},{"pmid":"32006593","id":"PMC_32006593","title":"STAT1 transcriptionally regulates the expression of S1PR1 by binding its promoter region.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32006593","citation_count":16,"is_preprint":false},{"pmid":"17983380","id":"PMC_17983380","title":"STAT1 gene variations, IgE regulation and atopy.","date":"2007","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/17983380","citation_count":16,"is_preprint":false},{"pmid":"39462396","id":"PMC_39462396","title":"α-Synuclein disrupts microglial autophagy through STAT1-dependent suppression of Ulk1 transcription.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39462396","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49237,"output_tokens":12184,"usd":0.165236,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23607,"output_tokens":7830,"usd":0.156892,"stage2_stop_reason":"end_turn"},"total_usd":0.322128,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"STAT1 (Stat91) is phosphorylated on a single tyrosine residue (Tyr701) in response to IFN-gamma, and phosphorylation of Tyr701 is required for nuclear translocation, DNA binding, and gene activation. The differentially spliced isoform Stat84, lacking the 38 C-terminal amino acids, was phosphorylated and translocated but did not activate transcription, demonstrating that the C-terminal transactivation domain is essential.\",\n      \"method\": \"Site-directed mutagenesis, phosphorylation mapping, nuclear translocation assay, transcriptional reporter assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of active-site residue with functional readouts (DNA binding, nuclear translocation, transcription); foundational paper replicated extensively\",\n      \"pmids\": [\"7690989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"STAT1 (91-kDa and 84-kDa proteins) are components of the multiprotein transcription factor ISGF-3, which is cytoplasmically activated by IFN-alpha and translocates to the nucleus to drive interferon-stimulated gene expression. ISGF-3 also contains a 113-kDa protein (STAT2) and a 48-kDa DNA-binding subunit.\",\n      \"method\": \"Protein purification, peptide sequencing, cDNA cloning, antibody validation (immunoprecipitation)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical purification and molecular cloning of complex components; foundational discovery replicated in multiple companion papers\",\n      \"pmids\": [\"1502203\", \"1502204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Inactive STAT1 (Stat91) is a monomer in the cytoplasm of unstimulated cells; IFN-gamma-induced Tyr701 phosphorylation drives formation of a stable homodimer. Only the phosphorylated dimer binds specific DNA sequences to activate transcription. Dimerization is mediated through SH2 domain recognition of the phosphotyrosyl peptide on the partner molecule.\",\n      \"method\": \"Dissociation/reassociation biochemical assays, SH2 mutant analysis, gel-shift DNA-binding assay, analytical biochemistry\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution of dimerization mechanism with mutagenesis; independently confirmed; SH2-pTyr interaction mechanism established with multiple methods\",\n      \"pmids\": [\"7510216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ISGF-3 formation requires phosphorylated Stat91 (STAT1); mutations blocking Tyr701 phosphorylation of the 91-kDa protein prevent ISGF-3 assembly. Stat113 (STAT2) is phosphorylated independently of Stat91/84, but phosphorylated STAT2 alone translocates to the nucleus much less efficiently in the absence of phosphorylated Stat91/84.\",\n      \"method\": \"Cell lines lacking Stat91/84, site-directed mutagenesis, co-immunoprecipitation, nuclear fractionation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic complementation with mutant cell lines and mutagenesis; multiple orthogonal methods\",\n      \"pmids\": [\"8197134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"JAK1 kinase is required for tyrosine phosphorylation of STAT1 (84- and 91-kDa) and STAT2 in response to both IFN-alpha/beta and IFN-gamma signaling. Mutant HeLa cells deficient in JAK1 fail to phosphorylate STAT1 on tyrosine and fail to mount a biological IFN response.\",\n      \"method\": \"Mutant cell line complementation analysis, immunoprecipitation, tyrosine phosphorylation assays, cell fusion analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic complementation in mutant cells; pathway position established; multiple methods\",\n      \"pmids\": [\"8114747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PIAS1 specifically inhibits STAT1-mediated gene activation by blocking the DNA-binding activity of activated STAT1. PIAS1 physically associates with phosphorylated STAT1 (requiring Tyr701 phosphorylation) but not with STAT2 or STAT3. Other PIAS family members do not bind STAT1.\",\n      \"method\": \"Co-immunoprecipitation, electrophoretic mobility shift assay (DNA-binding), transcriptional reporter assay, Tyr701 mutant analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, functional DNA-binding assay, mutagenesis to identify phosphorylation requirement; multiple orthogonal methods\",\n      \"pmids\": [\"9724754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"STAT1 is cleaved by a caspase during apoptosis (induced by double-stranded RNA and other apoptotic stimuli). The cleavage product is no longer able to mediate interferon-activated signal transduction.\",\n      \"method\": \"In vitro caspase cleavage assay, IFN signaling functional assay, apoptosis induction\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical demonstration of caspase cleavage with functional loss-of-signaling readout; single lab\",\n      \"pmids\": [\"9535846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Nuclear accumulation of phosphorylated STAT1 involves two separate steps: nuclear import and nuclear retention (mediated by nonspecific DNA binding of activated STAT1). Tyrosine dephosphorylation of STAT1 is required for nuclear export; DNA binding protects STAT1 from dephosphorylation in a sequence-specific manner. STAT1 undergoes continuous nucleocytoplasmic cycling sustained by kinase activity.\",\n      \"method\": \"Microinjection of recombinant STAT1, kinase/phosphatase inhibitor treatment, nuclear accumulation mutant characterization, antibody microinjection\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution by microinjection of recombinant protein, multiple mutants tested, pharmacological perturbations; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"12923054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"STAT1 translocation from the plasma membrane to the nuclear pore occurs by energy-independent diffusion (random walk), independent of the actin cytoskeleton or microtubules. Nuclear STAT1-GFP shows high mobility consistent with rapid association/dissociation with DNA and/or protein complexes.\",\n      \"method\": \"FRAP, FLIP, live-cell fluorescence microscopy with STAT1-GFP fusion protein, cytoskeletal disruption\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct live-cell imaging (FRAP/FLIP) with functional fusion protein; mechanistically informative localization experiment\",\n      \"pmids\": [\"11350940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Nuclear import and export signals of STAT1 reside within its DNA-binding domain. After phosphorylation and dimerization, STAT1's nuclear localization signal is revealed. Upon dephosphorylation and DNA dissociation in the nucleus, a CRM1-dependent nuclear export signal becomes accessible, mediating recycling to the cytoplasm.\",\n      \"method\": \"Domain mapping, export inhibitor studies, mutant STAT1 analysis\",\n      \"journal\": \"Science's STKE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — review summarizing prior experimental findings; single functional data source; mechanistic conclusions supported by cited experiments but this paper is a review\",\n      \"pmids\": [\"12915721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of unphosphorylated STAT1 (residues 1-683) complexed with an IFNgamma receptor phosphopeptide determined at 3.0 Å resolution. Unphosphorylated STAT1 is predominantly dimeric, mediated by N-domain (residues 1-123) interactions. Two interconvertible orientations of the core fragment are observed ('antiparallel' and 'parallel'), depending on SH2 domain orientation. The SH2 domain interaction with the IFNgamma receptor docking site is structurally resolved.\",\n      \"method\": \"X-ray crystallography (3.0 Å), static light scattering, analytical ultracentrifugation, co-immunoprecipitation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with orthogonal biophysical validation (AUC, light scattering, co-IP); multiple methods in one study\",\n      \"pmids\": [\"15780933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"STAT1 functions as a cytoplasmic attenuator of Runx2 (a key transcription factor for osteoblast differentiation) independently of IFN signaling. Loss of Stat1 in mice leads to excessive Runx2 activation and increased osteoblast differentiation, resulting in increased bone mass.\",\n      \"method\": \"Stat1-knockout mice, osteoblast differentiation assays, Runx2 nuclear translocation analysis\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with specific cellular phenotype and identified mechanism (cytoplasmic Runx2 attenuation); review paper summarizing original experimental findings\",\n      \"pmids\": [\"15546140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"STAT1 is an acetylated protein; acetylation is regulated by the balance between CBP (HAT) and HDACs. Both HDAC inhibitors and IFN-alpha induce STAT1 acetylation at Lys410 and Lys413. Only acetylated STAT1 interacts with NF-kappaB p65, reducing p65 DNA binding, nuclear localization, and expression of anti-apoptotic NF-kappaB target genes.\",\n      \"method\": \"STAT1 acetylation mutants (Lys410/413), co-immunoprecipitation, HDAC/HAT inhibitor treatment, reporter gene assay, DNA-binding assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis identifying acetylation sites, functional readouts (NF-κB binding/activity), biochemical interaction; multiple orthogonal methods in one study\",\n      \"pmids\": [\"16481475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A phosphorylation-acetylation switch regulates STAT1 signaling: CBP-mediated acetylation of STAT1 counteracts IFN-induced STAT1 phosphorylation, nuclear translocation, DNA binding, and target gene expression. Acetylation of STAT1 induces binding of T-cell protein tyrosine phosphatase (TC45/TCP45), which catalyzes dephosphorylation of STAT1 and promotes latency. HDAC3 removes the acetyl group, allowing re-phosphorylation.\",\n      \"method\": \"Biochemical assays, STAT1 acetylation/phosphorylation mutants, HAT/HDAC activity modulation, co-immunoprecipitation, transcriptional reporter assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis, biochemical reconstitution of the switch, identification of TC45 as the phosphatase recruited by acetylated STAT1; multiple orthogonal methods\",\n      \"pmids\": [\"19171783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"STAT1 directly interacts with cyclin D1 and CDK4 (G1 cell cycle regulatory proteins). IFN-gamma treatment reduces cyclin D1 protein levels via the proteasome pathway in a manner requiring STAT1 Ser727 (not Tyr701). This interaction and proteasomal degradation of cyclin D1 mediate cell cycle arrest, correlating with decreased pRb, cyclin E and increased p27 and p21.\",\n      \"method\": \"Co-immunoprecipitation, proteasome inhibitor treatment, STAT1 mutant analysis (Ser727, Tyr701), STAT1-deficient cell lines\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct co-IP of STAT1-cyclin D1/CDK4, site-specific mutagenesis, loss-of-function cell lines; single lab\",\n      \"pmids\": [\"21084836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Growth hormone (GH) rapidly induces tyrosine phosphorylation and nuclear translocation of STAT91 (STAT1) in vivo in rat liver. Activated STAT1 in the nucleus acquires DNA-binding activity toward a c-sis-inducible element (SIE) from the c-fos promoter, establishing that GH activates the STAT1 pathway.\",\n      \"method\": \"Western blotting of nuclear extracts, anti-phosphotyrosine immunoprecipitation, gel-mobility shift assay, in vivo GH treatment model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with nuclear fractionation, direct DNA-binding assay; single lab, two orthogonal methods\",\n      \"pmids\": [\"7510676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Angiotensin II acting through the AT1A receptor (a G-protein-coupled receptor) activates STAT1 (Stat91) or a related protein, inducing tyrosine phosphorylation and nuclear translocation of STAT1 and stimulating SIE-dependent DNA-binding activity. This response is sensitive to tyrosine kinase inhibition (genistein) and independent of new protein synthesis.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), subcellular fractionation, immunoprecipitation, tyrosine kinase inhibitor studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — EMSA plus fractionation plus inhibitor experiments; single lab, GPCR activation of STAT1 pathway established but mechanism upstream of STAT1 not fully resolved\",\n      \"pmids\": [\"7527386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PKCdelta activates STAT1 via phosphorylation of Ser727 in response to DNA damage (etoposide). STAT1 associates with PKCdelta, and nuclear co-localization of PKCdelta and STAT1 is required for PKCdelta-mediated apoptosis. STAT1beta lacking Ser727 does not support PKCdelta-induced apoptosis in STAT1-deficient cells.\",\n      \"method\": \"Co-immunoprecipitation, PKCdelta inhibition/depletion, STAT1 Ser727 mutant, STAT1-deficient cell line (U3A) complementation, transcriptional reporter assay, nuclear localization mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, genetic rescue with site-specific mutants, loss-of-function complementation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15322115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"STAT1 can be SUMOylated in vitro at Lys703 within the consensus SUMO site (702-IKTE-705). Mutation of K703 (K703R) in STAT1 enhances DNA binding and nuclear retention in STAT1-deficient MEFs, with modest effects on transcription and antiviral activity. Mutation of E705 (E705A) does not alter STAT1 activity, suggesting SUMO modification at Lys703 has limited physiological significance in vivo.\",\n      \"method\": \"In vitro SUMOylation assay, STAT1 mutant expression in STAT1-/- MEFs and macrophages, DNA-binding assay, nuclear retention assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of SUMOylation, mutant complementation in primary cells; results suggest limited in vivo relevance\",\n      \"pmids\": [\"16857984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"JAK/STAT1 pathway activation promotes HMGB1 hyperacetylation at its two nuclear localization sequences (NLS) and induces HMGB1 translocation from nucleus to cytoplasm. Pharmacological inhibition or genetic deletion of STAT1 abrogates LPS- or type I IFN-induced HMGB1 NLS acetylation and nuclear translocation.\",\n      \"method\": \"Mass spectrometry acetylation mapping, JAK inhibitor treatment, STAT1 genetic knockout, subcellular fractionation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry-based acetylation site mapping, genetic STAT1 knockout, pharmacological inhibition; multiple orthogonal methods\",\n      \"pmids\": [\"24469805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PARP14 mediates ADP-ribosylation of STAT1, which is suppressed by PARP9. ADP-ribosylation of STAT1 by PARP14 reduces STAT1 phosphorylation; mutations at ADP-ribosylation sites lead to increased STAT1 phosphorylation. PARP9 and PARP14 cross-regulate macrophage activation via this STAT1 ADP-ribosylation mechanism.\",\n      \"method\": \"Global proteomics, ADP-ribosylation assay, PARP9/14 silencing, phosphorylation analysis, site-directed mutagenesis of ADP-ribosylation sites\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical demonstration of ADP-ribosylation of STAT1 by PARP14, mutagenesis confirming functional sites, PARP9 antagonism; multiple methods in one study\",\n      \"pmids\": [\"27796300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"STAT1 undergoes linear ubiquitination at Lys511 and Lys652 by the LUBAC complex (via HOIP), which inhibits STAT1 binding to the IFN receptor IFNAR2, restricting STAT1 activation and maintaining type-I IFN signaling homeostasis. The deubiquitinase OTULIN removes linear ubiquitin from STAT1 upon IFN stimulation to facilitate activation. Viruses induce HOIP expression via NF-κB, thereby increasing STAT1 linear ubiquitination and suppressing antiviral IFN responses.\",\n      \"method\": \"Linear ubiquitination assay in intact cells, site-directed mutagenesis (K511, K652), OTULIN/HOIP knockdown and overexpression, IFNAR2 binding assay, HOIL-1L heterozygous mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical ubiquitination assay, mutagenesis of sites, deubiquitinase rescue, receptor-binding assay, in vivo mouse validation; multiple orthogonal methods\",\n      \"pmids\": [\"32123171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RNF220 E3 ubiquitin ligase mediates K63-linked polyubiquitination of STAT1 at residue Lys110, which promotes the interaction between STAT1 and JAK1, thereby enhancing STAT1 phosphorylation and activation. RNF220 deficiency impairs IFN signaling and ISG expression.\",\n      \"method\": \"Co-immunoprecipitation, K63-specific ubiquitination assay, site-directed mutagenesis (K110), RNF220 knockout cells and mice, JAK1-STAT1 interaction assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical ubiquitination assay with K63-linkage specificity, mutagenesis, JAK1 interaction assay, in vivo knockout; multiple orthogonal methods\",\n      \"pmids\": [\"32814877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Syk tyrosine kinase, acting downstream of RIG-I/MAVS signaling, directly phosphorylates STAT1 at Tyr701 at the early stage of influenza A virus infection independently of cytokines and JAKs. Syk deletion attenuates STAT1 phosphorylation and ISG expression; STAT1-Y701F knockin mice have suppressed antiviral response.\",\n      \"method\": \"Syk deletion (in vitro and in vivo), STAT1-Y701F knockin mice, RIG-I/MAVS pathway analysis, tyrosine phosphorylation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deletion and knockin mouse models with specific pathway placement; multiple in vitro and in vivo methods\",\n      \"pmids\": [\"33472080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Stat1-2 heterodimers form heterotetramers on tandem GAS sites through protein-protein interactions mediated by N-terminal regions of both Stat1 and Stat2. Deletion of 40 N-terminal amino acids from Stat1 abolishes heterotetramer formation without affecting heterodimer formation. ISGF3 also shows cooperative binding to tandem ISREs via N-terminal domain interactions.\",\n      \"method\": \"EMSA with tandem DNA elements, N-terminal deletion mutants, cooperative binding assays\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain deletion mutagenesis with DNA-binding assay; cooperative binding mechanism defined; single lab\",\n      \"pmids\": [\"9865492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PHLPP1 phosphatase dephosphorylates STAT1 at Ser727 in the nucleus, inhibiting STAT1 transcriptional activity, reducing its promoter residency, and decreasing expression of target genes involved in innate immunity. This function requires a bipartite nuclear localization signal in PHLPP1's N-terminal extension.\",\n      \"method\": \"PHLPP1 gene deletion (knockout mice), phosphorylation assays, chromatin immunoprecipitation (promoter occupancy), gene expression analysis, nuclear localization signal mapping\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with specific Ser727 phosphorylation readout, ChIP for promoter occupancy, mechanistic NLS mapping; multiple orthogonal methods\",\n      \"pmids\": [\"31408005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NKLAM E3 ubiquitin ligase mediates K63-linked ubiquitination of STAT1 at the IFNgamma receptor complex, which is required for STAT1 DNA-binding activity. NKLAM-deficient macrophages show hyperphosphorylated JAK1 and STAT1 but reduced STAT1 DNA-binding ability and reduced IFNgamma-target gene expression. NKLAM is transiently localized to the IFNgamma receptor complex during stimulation.\",\n      \"method\": \"K63-specific ubiquitination assay, co-immunoprecipitation, NKLAM-KO macrophages, DNA-binding (GAS sequence) assay, gene expression analysis\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical ubiquitination assay, receptor complex co-IP, DNA-binding functional assay; single lab\",\n      \"pmids\": [\"27570112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"STAT1 directly binds a regulatory element (NRE1) in the first intron of the Nampt gene during IFNgamma stimulation, driving NAMPT expression. NAMPT, the rate-limiting enzyme in NAD salvage synthesis, supports STAT1-dependent M1 macrophage gene expression through its impact on glycolytic processes.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), NRE1 disruption mouse model, NAMPT inhibition, scRNAseq\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing direct STAT1 binding, in vivo NRE1 disruption model; single lab\",\n      \"pmids\": [\"33976173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"STAT1 transcriptionally suppresses ULK1 (a kinase that controls autophagy initiation) by binding a regulatory sequence in the ULK1 5'-flanking region; mutation of this sequence increases ULK1 promoter activity and renders it unresponsive to mTOR inhibition. STAT1-deficient cells and mice show enhanced autophagic flux and increased ULK1 expression.\",\n      \"method\": \"Chromatin immunoprecipitation, promoter reporter assay with site mutation, STAT1-deficient cells and mice, autophagic flux measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP + promoter mutagenesis + genetic KO in vitro and in vivo; multiple orthogonal methods\",\n      \"pmids\": [\"28011640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT1 (pSTAT1) directly binds the FOXM1 promoter to transcriptionally down-regulate FOXM1 expression, as demonstrated by dual-luciferase reporter and ChIP assays. IFNgamma-mediated STAT1 phosphorylation suppresses FOXM1 and sensitizes pancreatic cancer cells to gemcitabine.\",\n      \"method\": \"Chromatin immunoprecipitation, dual-luciferase reporter assay, IFNgamma treatment, in vitro and in vivo cell models\",\n      \"journal\": \"Clinical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay establishing direct STAT1 binding to FOXM1 promoter; single lab\",\n      \"pmids\": [\"30782607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In naive cells, unphosphorylated STAT2 forms a heterodimer with unphosphorylated STAT1 in an inactive anti-parallel conformation. A novel phosphorylation of STAT2 at Thr404 (mouse Thr403) by IKK-epsilon (activated by viral infection) disrupts this U-STAT1-U-STAT2 dimer, facilitating tyrosine phosphorylation of STAT1 and STAT2 and enhancing ISGF3 DNA-binding activity. Mice with T403A knockin are highly susceptible to viral infection.\",\n      \"method\": \"Electron microscopy structural analysis, site-directed mutagenesis (T404A), IKK-epsilon kinase assay, T403A knockin mice, ISGF3 DNA-binding assay\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EM structure plus mutagenesis plus in vivo knockin mouse phenotype; multiple orthogonal methods in one study\",\n      \"pmids\": [\"32759968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nuclear RNA helicase DHX9 directly binds STAT1 upon IFN stimulation and recruits RNA Pol II to interferon-stimulated gene (ISG) promoter regions to facilitate STAT1-mediated ISG transcription. In vivo DHX9 knockout (myeloid- or hepatocyte-specific) combined with STAT1 knockout demonstrates that DHX9 acts downstream of type I IFN and requires STAT1 for antiviral gene regulation.\",\n      \"method\": \"Co-immunoprecipitation of DHX9-STAT1, chromatin immunoprecipitation (Pol II recruitment), conditional DHX9/STAT1 double-knockout mice, antiviral challenge\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ChIP, epistatic genetic knockouts; single lab\",\n      \"pmids\": [\"36735791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"STAT1 acts downstream of PDGFRbeta signaling to mediate autoinflammation and tissue wasting. Genetic knockout of Stat1 in Pdgfrb gain-of-function mice rescues autoinflammation and converts the wasting phenotype to overgrowth. Deletion of IFN receptors (Ifnar1 or Ifngr1) does not rescue the Pdgfrb wasting phenotype, demonstrating that STAT1 mediates PDGFRbeta-driven autoinflammation independently of IFN receptor signaling.\",\n      \"method\": \"Genetic epistasis (Stat1-/- x Pdgfrb+/D849V double mutants), Ifnar1 and Ifngr1 knockout crosses, phenotypic analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic epistasis with multiple knockout combinations; IFN-independence established by receptor deletion; replicated in multiple cross-bred mouse lines\",\n      \"pmids\": [\"28924035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LPS-induced Toll-like receptor 4 endocytosis activates IκB kinase (IKK), which phosphorylates STAT1 at Thr748. This Thr748 phosphorylation promotes macrophage inflammatory responses while restricting IFN and anti-inflammatory responses. Phospho-deficient T748A knockin mice are resistant to LPS-induced lethality without disrupting canonical IFN-Tyr701 signaling, establishing Thr748 as an IFN-independent inflammatory phosphorylation switch.\",\n      \"method\": \"Genetically engineered T748A knockin mice, IKK kinase assay, LPS challenge model, macrophage depletion, phosphorylation site-specific analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — knockin mouse with defined point mutation, in vitro kinase assay, in vivo lethality model with macrophage depletion rescue; multiple methods\",\n      \"pmids\": [\"38621137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT1 gain-of-function (GOF) pathogenic variants cause elevated total STAT1 protein levels (via increased STAT1 mRNA) rather than impaired dephosphorylation. The rate of STAT1 dephosphorylation after JAK inhibition is actually faster in GOF patient cells than healthy controls. The elevated peak pSTAT1 in GOF patients is driven by higher total STAT1 protein available for phosphorylation.\",\n      \"method\": \"Flow cytometry (total STAT1 protein), immunoblot, qRT-PCR (mRNA), cycloheximide chase (protein degradation), JAK inhibitor (ruxolitinib) dephosphorylation kinetics in patient PBMCs\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in patient cells; challenges prior delayed-dephosphorylation hypothesis; single study\",\n      \"pmids\": [\"31354696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCT6A interacts with STAT1 protein and protects it from ubiquitin-mediated proteasomal degradation, thereby stabilizing STAT1. Stabilized STAT1 then promotes transcription of hexokinase 2 (HK2), driving aerobic glycolysis in lung adenocarcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation, ubiquitination assay, CCT6A silencing\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, MS, ChIP, and ubiquitination assay; single lab with multiple methods\",\n      \"pmids\": [\"38750462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAP (adhesion and degranulation-protein adaptor protein) interacts with STAT1 and competes with importin alpha5 for STAT1 binding, thereby restraining STAT1 nuclear entry. ADAP deficiency potentiates STAT1 nuclear translocation, leading to enhanced FcγRI/IV transcription and increased macrophage phagocytosis. Pharmacological inhibition of STAT1 or disruption of the STAT1-importin alpha5 interaction relieves thrombocytopenia in Adap-/- mice.\",\n      \"method\": \"Co-immunoprecipitation (ADAP-STAT1-importin α5 complex), ADAP-/- mice, STAT1 nuclear translocation assay, FcγR gene expression, pharmacological STAT1 inhibition\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP establishing ternary complex, genetic knockout with defined phenotype, pharmacological rescue; single lab\",\n      \"pmids\": [\"35637282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"STAT1 transcriptionally suppresses ULK1 (Ulk1) expression in microglia. Alpha-synuclein PFF activates STAT1 through Toll-like receptor 4-dependent signaling, causing STAT1-mediated suppression of Ulk1 transcription and impairment of microglial autophagy. Conditional microglial Stat1 knockout restores ULK1 expression and autophagy.\",\n      \"method\": \"Luciferase reporter assay (Ulk1 promoter), Stat1 knockdown and overexpression, conditional microglial Stat1-KO mice, TLR4 dependency analysis, autophagy flux measurements\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay, Stat1 KO/KD, in vivo conditional knockout; single lab with multiple methods\",\n      \"pmids\": [\"39462396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"STAT1 is phosphorylated and activated by MST4 kinase in macrophages; MST4 silencing directly inhibits STAT1 phosphorylation, which is essential for M1 macrophage polarization. Macrophage-specific Mst4 knockout in an ITP mouse model reduces M1 macrophage numbers and attenuates thrombocytopenia.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, phosphoproteomics, RNA-seq, Mst4 conditional knockout mice, macrophage M1 polarization assays\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP/MS identifying MST4-STAT1 interaction, phosphoproteomics, in vivo conditional KO; single lab\",\n      \"pmids\": [\"37833401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IRF1 promotes STAT1 phosphorylation at Tyr701 and subsequent GAS-element DNA binding through an indirect mechanism requiring IRF1 transactivation domain-dependent gene products (not direct IRF1-STAT1 interaction). IRF1-induced STAT1 activation is not blocked by IFN-beta or IFN-gamma antibodies, suggesting a novel cytokine mediates the effect. IRF1 deficiency reduces IFN-gamma-induced STAT1 phosphorylation persistence, establishing a positive feedback loop.\",\n      \"method\": \"Transient IRF1 overexpression in HEK293 cells, GAS-reporter assay, JAK1 phosphorylation analysis, IRF1-knockout cells (CRISPR), IRF1 complementation\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout plus complementation, reporter assay; indirect mechanism (no direct IRF1-STAT1 binding detected); single lab\",\n      \"pmids\": [\"29893425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRMT6 and STAT1 interact and synergistically regulate transcription of ACSL1. PRMT6 downregulation in diabetic nephropathy allows STAT1 to drive increased ACSL1 expression, promoting lipid peroxidation and ferroptosis in kidney cells. STAT1-specific inhibitor fludarabine delays DN progression in mouse models.\",\n      \"method\": \"Co-immunoprecipitation (PRMT6-STAT1), chromatin immunoprecipitation (STAT1 at ACSL1 promoter), PRMT6-/- mice, lipidomic analysis\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ChIP, genetic knockout, in vivo model; single lab\",\n      \"pmids\": [\"39134684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"STAT1 functions as a transcriptional suppressor of HIF1A by binding to the HIF1A promoter. Ablation of ATG7 upregulates STAT1 expression (via a ZNF148-dependent autophagy-independent mechanism), increases STAT1 binding to the HIF1A promoter, and suppresses HIF1A expression, thereby inhibiting angiogenesis.\",\n      \"method\": \"Chromatin immunoprecipitation (STAT1 binding HIF1A promoter), endothelial-specific Atg7 KO mice, fludarabine STAT1 inhibition, tube formation assay\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating STAT1 binding to HIF1A promoter, genetic KO, in vivo rescue; single lab\",\n      \"pmids\": [\"36300763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Bcl6 directly binds the Stat1 promoter (demonstrated by ChIP) and transcriptionally represses Stat1 expression in osteoblasts. Loss of Bcl6 elevates Stat1 mRNA and protein, which attenuates nuclear translocation of Runx2, inhibiting osteoblast differentiation. Double knockout of Bcl6 and Stat1 rescues the bone phenotype of Bcl6-deficient mice.\",\n      \"method\": \"Chromatin immunoprecipitation (Bcl6 at Stat1 promoter), Bcl6-/- x Stat1-/- double-knockout mice, osteoblast differentiation assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, genetic epistasis in double-KO mice; single lab; establishes Bcl6-STAT1-Runx2 axis\",\n      \"pmids\": [\"25597995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"S-glutathionylation of STAT1 (oxidative modification) induced by oxidative stress causes aberrant hyperactivation of STAT1 signaling in microglia, contributing to neuroinflammation under hypoxia. Both phosphorylation and S-glutathionylation of STAT1 are induced by hypoxia and drive M1 microglia activation.\",\n      \"method\": \"S-glutathionylation assay, STAT1 silencing, hypoxia model in BV2 cells, M1 phenotype markers\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, cell line model only, S-glutathionylation detection without site mapping or mutagenesis validation\",\n      \"pmids\": [\"31121156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"STAT1 occupies a conserved binding element at IRF1 and STAT1 co-regulated ISG enhancers. IRF1 binds proximal or distant ISG sites more frequently than STAT1, and STAT1 almost always binds together with IRF1, while most IRF1 binding events are isolated. Dual STAT1+IRF1 binding at remote or proximal enhancers distinguishes IFNgamma-responsive from cell-type-resistant ISGs.\",\n      \"method\": \"ChIP-seq (STAT1 and IRF1 binding in multiple cell types), in vitro EMSA with SNP variants, in vivo ChIP validation\",\n      \"journal\": \"BMC molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with in vitro and in vivo validation; multiple cell types; single lab\",\n      \"pmids\": [\"28274199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"STAT1 directly binds the upstream region (-29 to -12 bp) of the S1PR1 promoter and stimulates S1PR1 transcription. STAT1 knockdown reduces S1PR1 mRNA and protein; STAT1 overexpression increases S1PR1 levels. IFN-gamma activation of STAT1 increases S1PR1 expression.\",\n      \"method\": \"EMSA, chromatin immunoprecipitation, promoter-deletion reporter assay, STAT1 knockdown and overexpression\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus ChIP plus reporter assay; single lab\",\n      \"pmids\": [\"32006593\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"STAT1 is a latent cytoplasmic transcription factor that, upon IFN (and other cytokine) stimulation, is phosphorylated on Tyr701 by JAK1 (or Syk in viral infection), forming homodimers (GAS-binding) or heterodimers/ISGF3 with STAT2 and IRF9 (ISRE-binding) via SH2–phosphotyrosine interactions; these active dimers undergo importin-dependent nuclear import, bind DNA to drive ISG transcription, and are recycled to the cytoplasm after TC45-mediated dephosphorylation once released from DNA. A multilayered post-translational regulatory code—including Ser727 phosphorylation (by PKCδ, p38), acetylation at Lys410/413 (by CBP, reversed by HDAC3), K63-linked ubiquitination (by RNF220 at K110, by NKLAM), linear ubiquitination (by LUBAC at K511/K652, removed by OTULIN), ADP-ribosylation (by PARP14, counteracted by PARP9), SUMOylation (at K703), and Thr748 phosphorylation (by IKK, LPS-dependent)—fine-tunes STAT1 activation, nuclear retention, DNA binding, and interactions with NF-κB p65, cyclin D1/CDK4, importin α5, and PIAS1, enabling STAT1 to control ISG expression, cell-cycle arrest, autophagy, apoptosis, osteoblast differentiation, and inflammatory gene programs.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"STAT1 is a latent cytoplasmic transcription factor that converts cytokine receptor engagement into interferon-stimulated gene (ISG) transcription, governing antiviral defense, cell-cycle arrest, autophagy, apoptosis, and inflammatory gene programs [#0, #1]. In response to IFN-gamma, JAK1 phosphorylates STAT1 on a single residue, Tyr701, which is required for homodimer formation, nuclear translocation, DNA binding, and gene activation; the C-terminal transactivation domain is independently essential for transcription [#0, #4]. Dimerization occurs through reciprocal SH2-domain recognition of the partner's phosphotyrosine, and only the phosphorylated dimer binds DNA [#2], while in the IFN-alpha response phosphorylated STAT1 assembles with STAT2 and a DNA-binding subunit into the ISGF3 complex that drives ISG expression [#1, #3]. Crystallographic and biophysical analysis show that unphosphorylated STAT1 is already dimeric through N-domain contacts and interconverts between antiparallel and parallel orientations, and that the SH2 domain docks onto the IFN-gamma receptor phosphopeptide [#10]. Nuclear accumulation proceeds in two steps—importin-dependent import followed by DNA-binding-mediated retention—and recycling requires tyrosine dephosphorylation and CRM1-dependent export, with continuous nucleocytoplasmic cycling sustained by ongoing kinase activity [#7, #9]. A dense post-translational code tunes this cycle: Ser727 phosphorylation by PKCdelta links STAT1 to DNA-damage-induced apoptosis [#17]; acetylation at Lys410/413 by CBP (reversed by HDAC3) recruits the phosphatase TC45 to drive latency and redirects STAT1 to antagonize NF-kappaB p65 [#12, #13]; K63-linked ubiquitination by RNF220 at Lys110 and by NKLAM promotes JAK1 association and DNA binding [#22, #26]; linear ubiquitination by LUBAC at Lys511/Lys652, removed by OTULIN, restrains receptor engagement [#21]; and PARP14-mediated ADP-ribosylation, antagonized by PARP9, suppresses phosphorylation [#20]. Beyond canonical JAK signaling, STAT1 is activated by Syk downstream of RIG-I/MAVS during viral infection [#23] and by IKK-phosphorylation at Thr748, an IFN-independent inflammatory switch [#33]. As a transcription factor STAT1 directly activates targets including NAMPT, S1PR1, and HK2 and represses ULK1, FOXM1, and HIF1A, thereby controlling macrophage metabolism, autophagy, and angiogenesis [#27, #28, #41, #45], and it acts independently of IFN receptors as a cytoplasmic attenuator of Runx2 in osteoblasts and as a downstream effector of PDGFRbeta-driven autoinflammation [#11, #32]. Gain-of-function disease variants act by elevating total STAT1 protein and thus peak phospho-STAT1 rather than by impairing dephosphorylation [#34].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established that STAT1 is a physical component of a cytokine-activated nuclear transcription complex, defining it as a signal-dependent transcription factor rather than a constitutive regulator.\",\n      \"evidence\": \"Protein purification, peptide sequencing, and cDNA cloning of the ISGF-3 complex activated by IFN-alpha\",\n      \"pmids\": [\"1502203\", \"1502204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the activating modification\", \"Stoichiometry and assembly order of ISGF3 subunits unresolved at this stage\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Pinpointed the single activating event—Tyr701 phosphorylation—and separated activation from transcriptional output by showing the C-terminal transactivation domain is independently required.\",\n      \"evidence\": \"Site-directed mutagenesis, phosphorylation mapping, and reporter assays comparing full-length and C-terminally truncated isoforms in IFN-gamma response\",\n      \"pmids\": [\"7690989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the kinase responsible\", \"Dimerization mechanism not yet defined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined the dimerization mechanism and upstream kinase, showing phospho-Tyr701 drives SH2-mediated homodimer formation and that JAK1 is the kinase required for STAT1 activation by both type I and II IFNs.\",\n      \"evidence\": \"Dissociation/reassociation biochemistry with SH2 mutants and gel-shift assays; JAK1-deficient mutant cell complementation\",\n      \"pmids\": [\"7510216\", \"8114747\", \"8197134\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the SH2-phosphopeptide docking not yet resolved\", \"Did not address non-IFN receptor inputs\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showed STAT1 activation is not restricted to interferons, extending it to growth hormone and GPCR (angiotensin II/AT1A) signaling and broadening its physiological scope.\",\n      \"evidence\": \"In vivo GH liver model and AT1A receptor activation with nuclear fractionation, EMSA, and tyrosine kinase inhibitor studies\",\n      \"pmids\": [\"7510676\", \"7527386\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinases coupling GH/GPCR receptors to STAT1 not fully defined\", \"Physiological gene targets in these contexts not mapped\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified negative regulation and cooperative DNA recognition, with PIAS1 blocking activated STAT1 DNA binding and N-domain contacts driving heterotetramer formation on tandem GAS/ISRE sites.\",\n      \"evidence\": \"Reciprocal co-IP, EMSA with Tyr701 and N-terminal deletion mutants; caspase cleavage abolishing signaling during apoptosis\",\n      \"pmids\": [\"9724754\", \"9865492\", \"9535846\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PIAS1 acts catalytically or stoichiometrically not defined\", \"In vivo significance of heterotetramers not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the nuclear trafficking cycle: import plus DNA-binding-mediated retention, dephosphorylation-dependent CRM1 export, and energy-independent diffusion to the nuclear pore sustained by continuous kinase activity.\",\n      \"evidence\": \"Microinjection of recombinant STAT1, FRAP/FLIP live imaging of STAT1-GFP, kinase/phosphatase inhibitors, and domain mapping\",\n      \"pmids\": [\"12923054\", \"11350940\", \"12915721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the nuclear phosphatase not yet established here\", \"Import receptor identity addressed only later\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided the structural model of STAT1, showing unphosphorylated dimers held by N-domain contacts and interconverting antiparallel/parallel conformations with the SH2 domain docked on the IFN-gamma receptor peptide.\",\n      \"evidence\": \"X-ray crystallography at 3.0 A with analytical ultracentrifugation, light scattering, and co-IP\",\n      \"pmids\": [\"15780933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the phosphorylated DNA-bound dimer not in this study\", \"Full-length C-terminal transactivation domain not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed an IFN-independent cytoplasmic role, with STAT1 attenuating Runx2 to restrain osteoblast differentiation and bone mass.\",\n      \"evidence\": \"Stat1-knockout mice with osteoblast differentiation and Runx2 nuclear translocation assays\",\n      \"pmids\": [\"15546140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of cytoplasmic Runx2 sequestration not defined\", \"Whether STAT1 modifications regulate this function unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Opened the post-translational regulatory layer by identifying acetylation (Lys410/413, CBP-dependent) as a modification that reroutes STAT1 to antagonize NF-kappaB p65 and SUMOylation at Lys703 as a modest DNA-binding/retention modulator.\",\n      \"evidence\": \"Acetylation- and SUMO-site mutants, co-IP, HAT/HDAC modulation, and in vitro SUMOylation with complementation in STAT1-/- cells\",\n      \"pmids\": [\"16481475\", \"16857984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo significance of K703 SUMOylation appears limited\", \"Crosstalk between acetylation and phosphorylation not yet defined here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a phosphorylation-acetylation switch, showing CBP acetylation recruits the phosphatase TC45 to dephosphorylate STAT1 and impose latency, reversed by HDAC3.\",\n      \"evidence\": \"Acetylation/phosphorylation mutants, HAT/HDAC modulation, co-IP, and reporter assays reconstituting the switch\",\n      \"pmids\": [\"19171783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the switch operates at all receptors not tested\", \"Spatial coordination of TC45 recruitment unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected STAT1 to cell-cycle control via direct cyclin D1/CDK4 binding and Ser727-dependent proteasomal cyclin D1 degradation, mediating IFN-gamma-induced arrest.\",\n      \"evidence\": \"Co-IP, proteasome inhibition, and Ser727/Tyr701 mutant analysis in STAT1-deficient cells\",\n      \"pmids\": [\"21084836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether degradation is direct or transcriptionally mediated not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed STAT1 governs inflammatory output beyond ISG transcription by promoting HMGB1 NLS hyperacetylation and nucleocytoplasmic translocation.\",\n      \"evidence\": \"Mass spectrometry acetylation mapping, JAK inhibition, STAT1 knockout, and subcellular fractionation\",\n      \"pmids\": [\"24469805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase linking STAT1 to HMGB1 not identified\", \"Direct vs indirect mechanism unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established ubiquitin and ADP-ribosylation control of STAT1, with NKLAM K63-ubiquitination required for DNA binding, PARP14 ADP-ribosylation suppressing phosphorylation (antagonized by PARP9), and STAT1 directly driving NAMPT for macrophage metabolic reprogramming.\",\n      \"evidence\": \"K63-specific ubiquitination assays in NKLAM-KO macrophages; ADP-ribosylation with PARP9/14 silencing and site mutagenesis; ChIP with NRE1 disruption mouse\",\n      \"pmids\": [\"27570112\", \"27796300\", \"33976173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How K63 ubiquitination mechanistically enables DNA binding unclear\", \"Interplay among competing modifications not integrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified STAT1 as a transcriptional repressor of autophagy via direct suppression of ULK1, integrating STAT1 with mTOR-regulated autophagic flux.\",\n      \"evidence\": \"ChIP, promoter reporter mutagenesis, and STAT1-deficient cells and mice with autophagic flux measurement\",\n      \"pmids\": [\"28011640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ULK1 repression requires Tyr701 vs Ser727 not defined\", \"Cofactors at the ULK1 promoter unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined STAT1-IRF1 enhancer co-occupancy as a determinant of ISG responsiveness and revealed an IFN-receptor-independent role for STAT1 downstream of PDGFRbeta in autoinflammation and tissue wasting.\",\n      \"evidence\": \"ChIP-seq of STAT1/IRF1 across cell types; genetic epistasis of Stat1-/- with Pdgfrb gain-of-function and Ifnar1/Ifngr1 knockout crosses\",\n      \"pmids\": [\"28274199\", \"28924035\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PDGFRbeta activates STAT1 without IFN receptors not defined\", \"Determinants of STAT1/IRF1 co-binding selectivity unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Expanded regulators and targets: PHLPP1 dephosphorylates nuclear Ser727 to limit promoter residency, IRF1 sustains STAT1 Tyr701 phosphorylation via an indirect feedback loop, and STAT1 represses FOXM1 to sensitize tumor cells.\",\n      \"evidence\": \"PHLPP1-KO mice with ChIP; IRF1-KO/complementation with GAS reporters; ChIP and luciferase at the FOXM1 promoter\",\n      \"pmids\": [\"31408005\", \"29893425\", \"30782607\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cytokine mediating IRF1-driven STAT1 activation not identified\", \"PHLPP1 substrate selectivity within the nucleus not fully mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Reframed the basis of STAT1 gain-of-function disease, showing elevated total STAT1 protein—not impaired dephosphorylation—drives high peak phospho-STAT1.\",\n      \"evidence\": \"Flow cytometry, immunoblot, qRT-PCR, cycloheximide chase, and ruxolitinib dephosphorylation kinetics in patient PBMCs\",\n      \"pmids\": [\"31354696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism elevating STAT1 mRNA in patients not defined\", \"Single patient-cell study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved layered ubiquitin and conformational control of STAT1 activation, with LUBAC linear ubiquitination (OTULIN-reversed) restraining receptor binding, RNF220 K63-ubiquitination at Lys110 promoting JAK1 association, and IKK-epsilon phosphorylation of STAT2 disrupting the inactive U-STAT1-U-STAT2 dimer to enable ISGF3 assembly.\",\n      \"evidence\": \"Linear/K63 ubiquitination assays with site mutagenesis, DUB/E3 manipulation, receptor-binding and JAK1 interaction assays, EM structure, and T403A/HOIL-1L mouse models\",\n      \"pmids\": [\"32123171\", \"32814877\", \"32759968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How competing ubiquitin marks are temporally coordinated unresolved\", \"Stoichiometry of the U-STAT1-U-STAT2 pool unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended STAT1's transcriptional repertoire to angiogenesis and signaling regulation, repressing HIF1A and activating S1PR1, with additional oxidative S-glutathionylation reported to hyperactivate STAT1.\",\n      \"evidence\": \"ChIP/EMSA/reporter assays at HIF1A and S1PR1 promoters with knockdown/overexpression; S-glutathionylation assay in BV2 microglia\",\n      \"pmids\": [\"36300763\", \"32006593\", \"31121156\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"S-glutathionylation site not mapped or validated by mutagenesis (Low-confidence)\", \"Context-dependence of activation vs repression at different promoters unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified cytokine-independent activation and protein-level stabilization of STAT1, with Syk phosphorylating Tyr701 downstream of RIG-I/MAVS during influenza and CCT6A protecting STAT1 from proteasomal degradation to drive HK2-dependent glycolysis.\",\n      \"evidence\": \"Syk deletion and STAT1-Y701F knockin mice; co-IP/MS, ChIP, and ubiquitination assays with CCT6A silencing\",\n      \"pmids\": [\"33472080\", \"38750462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Syk acts at the receptor or in the cytosol not fully defined\", \"CCT6A finding from a single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed cytoplasmic gating of STAT1 nuclear entry, with ADAP competing against importin alpha5 for STAT1 binding to restrain nuclear translocation and FcgammaR-driven phagocytosis.\",\n      \"evidence\": \"Co-IP of ADAP-STAT1-importin alpha5, ADAP-/- mice, nuclear translocation and FcgammaR expression assays, and pharmacological STAT1 inhibition\",\n      \"pmids\": [\"35637282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ADAP regulation is modification-dependent unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected STAT1 to transcriptional machinery recruitment and additional disease contexts, with DHX9 bridging STAT1 to RNA Pol II at ISG promoters, MST4 phosphorylating STAT1 for M1 polarization, and STAT1 repressing microglial Ulk1 in synucleinopathy.\",\n      \"evidence\": \"Co-IP and ChIP with conditional DHX9/STAT1 double-KO mice; co-IP/MS and Mst4 conditional KO; luciferase, KO/KD, and conditional microglial Stat1-KO with TLR4 dependency\",\n      \"pmids\": [\"36735791\", \"37833401\", \"39462396\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs scaffold role of DHX9 in Pol II loading not separated\", \"Each finding from a single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined an IFN-independent inflammatory phosphorylation switch and further metabolic/disease roles, with IKK phosphorylating STAT1 at Thr748 to bias macrophages toward inflammation and STAT1 partnering with PRMT6 to drive ACSL1-dependent ferroptosis.\",\n      \"evidence\": \"T748A knockin mice with IKK kinase assay and LPS lethality model; co-IP and ChIP with PRMT6-/- mice and lipidomics\",\n      \"pmids\": [\"38621137\", \"39134684\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Thr748 phosphorylation mechanistically suppresses IFN output unresolved\", \"PRMT6-STAT1 finding from a single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the dense array of competing post-translational modifications, cytoplasmic gating factors, and alternative kinases is integrated to set STAT1 activity in a given cell and stimulus remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified quantitative model of PTM crosstalk on STAT1\", \"Stimulus- and cell-type-specific selection between JAK1, Syk, IKK, MST4, and PKCdelta inputs not defined\", \"Determinants directing STAT1 to activate vs repress specific target promoters unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 27, 28, 29, 41, 45]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 7, 24, 26, 44]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 7, 11, 36]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 7, 9, 25]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [25, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 21, 23, 27, 33]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 27, 28, 29, 41, 45]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 22, 23, 32, 39]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [28, 37]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [21, 22, 26, 20, 35]}\n    ],\n    \"complexes\": [\"ISGF3\"],\n    \"partners\": [\"STAT2\", \"JAK1\", \"PIAS1\", \"CBP\", \"RNF220\", \"DHX9\", \"PARP14\", \"importin alpha5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}